var title_f1_30_1504="Rx type 2 diabetes mellitus";
var content_f1_30_1504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Management of type 2 diabetes mellitus in children and adolescents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 648px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FPG: fasting plasma glucose; HbA1c: hemoglobin A1c (glycosylated hemoglobin).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1504=[""].join("\n");
var outline_f1_30_1504=null;
var title_f1_30_1505="Calculator: DVT probability: Wells score system";
var content_f1_30_1505=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"DVTScoreWells_form\" name=\"DVTScoreWells_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: DVT probability: Wells score system",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Clinical Findings",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Paralysis, paresis or recent orthopedic casting of lower extremity (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Recently bedridden (more than 3 days) or major surgery within past 4 weeks (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Localized tenderness in deep vein system (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Swelling of entire leg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Calf swelling  3 cm greater than other leg (measured 10 cm below the tibial tuberosity) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Pitting edema greater in the symptomatic leg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Collateral non varicose superficial veins (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Active cancer or cancer treated within 6 months (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"DVTScoreWells_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Alternative diagnosis more likely than DVT (Baker's cyst, cellulitis, muscle damage, superficial venous thrombosis, post phlebitic syndrome, inguinal lymphadenopathy, external venous compression) (-2 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          DVT Risk Score Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3-8 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High probability of DVT",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           1-2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Moderate probability",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           -2-0 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low Probability",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Wells PS, Anderson DR, Bormanis J, et. al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management.",
"        <i>",
"         Lancet",
"        </i>",
"        . 1997 Dec 20-27;350(9094):1795-8.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"DVTScoreWells_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1505=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function DVTScoreWells_fx() {",
"with(document.DVTScoreWells_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8.checked){",
"Score = Score + 1;",
"}",
"if (cc9.checked){",
"Score = Score + -2;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 3) && (Score <= 8)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 1) && (Score <= 2)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= -2) && (Score <= 0)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f1_30_1505=null;
var title_f1_30_1506="Ced genes phagocytosis";
var content_f1_30_1506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Ced genes and their mammalian homologs that encode proteins responsible for phagocytosis of apoptotic cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Keith Elkon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1506=[""].join("\n");
var outline_f1_30_1506=null;
var title_f1_30_1507="Terbinafine (topical): Pediatric drug information";
var content_f1_30_1507=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terbinafine (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=see_link\">",
"    see \"Terbinafine (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39763?source=see_link\">",
"    see \"Terbinafine (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9566190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LamISIL AT&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9566191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lamisil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F994503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F994514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=see_link\">",
"      see \"Terbinafine (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, gel, solution: Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Athlete's foot (tinea pedis): OTC/prescription formulations: Apply to affected area twice daily for at least 1 week, not to exceed 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ringworm (tinea corporis) and jock itch (tinea cruris): OTC formulations: Apply cream to affected area once or twice daily for at least 1 week, not to exceed 4 weeks; apply gel or solution once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, solution: Adults: Tinea versicolor: Prescription formulation: Apply to affected area twice daily for 1 week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride: 1% (12 g [DSC], 15 g, 24 g [DSC], 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LamISIL AT&reg;: 1% (12 g, 15 g, 24 g, 30 g, 36 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LamISIL AT&reg;: 1% (6 g, 12 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LamISIL AT&reg;: 1% (30 mL) [contains ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9566194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10526788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply to clean, dry affected area in sufficient quantity to cover; avoid contact with eyes, nose, mouth, or other mucous membranes. Do not use occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F994511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Store at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Store at 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F); do not refrigerate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F994504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antifungal for the treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) (OTC/prescription formulations); tinea versicolor (prescription formulations)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9566186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Terbinafine may be confused with terbutaline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9568010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning, contact dermatitis, dryness, exfoliation, irritation, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F994506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terbinafine or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F994507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical formulations (gel, cream, or solution) are not for ophthalmic, oral, or intravaginal use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F247713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9568004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies with systemic terbinafine. Systemic absorption is limited following topical application.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F994512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic allylamine derivative which inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell wall and results in fungal cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F994513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Children and Adults: Limited (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributed to sebum and skin predominantly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 14-35 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F994515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39763?source=see_link\">",
"      see \"Terbinafine (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, nose, or mouth. Report irritation, itching, or burning of skin around nail. Full clinical effect may require several months due to the time required for a new nail to grow.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15935 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1507=[""].join("\n");
var outline_f1_30_1507=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566190\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566191\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994503\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994514\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247718\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566194\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526788\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994511\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994504\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566186\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9568010\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994506\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994507\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300113\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247713\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9568004\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994512\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994513\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F994515\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=related_link\">",
"      Terbinafine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/46/9957?source=related_link\">",
"      Terbinafine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/4/19526?source=related_link\">",
"      Terbinafine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=related_link\">",
"      Terbinafine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39763?source=related_link\">",
"      Terbinafine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1508="Potassium phosphate: Patient drug information";
var content_f1_30_1508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium phosphate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=see_link\">",
"     see \"Potassium phosphate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"     see \"Potassium phosphate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neutra-Phos&reg;-K [OTC] [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium phosphate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low calcium levels, very bad kidney disease, low magnesium levels, high phosphate levels, or high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12101 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1508=[""].join("\n");
var outline_f1_30_1508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212067\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012657\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012656\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012661\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012662\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012664\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012659\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012665\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012666\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/62/27622?source=related_link\">",
"      Potassium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=related_link\">",
"      Potassium phosphate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1509="Care after sexual assault";
var content_f1_30_1509=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Care after sexual assault (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/30/1509/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1509/contributors\" id=\"au4499\">",
"       Carol K Bates, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/30/1509/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1509/contributors\" id=\"se7269\">",
"       Ron M Walls, MD, FRCPC, FAAEM",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/30/1509/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1509/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/30/1509?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Sexual assault is defined as any sexual act performed by one (or more) person(s) on another without consent. It may include the use or threat of force. In some cases, the person does not give consent to have sex because he or she is unconscious or otherwise incapacitated. A person may be raped by a stranger, an acquaintance or date, or a family member. Rape is a legal term and in the United States it refers to any penetration of a body orifice (mouth, vagina, or anus) involving force or the threat of force or incapacity (ie, associated with young or old age, cognitive or physical disability, or drug or alcohol intoxication) without consent.",
"    </p>",
"    <p>",
"     One in three women in the United States will be a victim of sexual assault sometime in her life; 7 to 10 percent of rape victims are male [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/1\">",
"      1",
"     </a>",
"     ]. One in four women will experience rape or attempted rape during her college years. Large population-based surveys indicate a lifetime prevalence of 13 to 39 percent among women and 3 percent among men [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/2,3\">",
"      2,3",
"     </a>",
"     ]. Only 10 to 15 percent of all sexual assaults are reported to police. Rape victims are less likely to report assault when the assailant is known to them.",
"    </p>",
"    <p>",
"     Sexual assaults that are facilitated by the use of alcohol and drugs, which in some cases are voluntarily ingested by the victim, are increasingly recognized and are more common than classic forcible assaults among college students [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/4,5\">",
"      4,5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     This article is intended as a general guide for victims and family members or friends of a person who has been sexually assaulted. You should seek specific guidance about your situation from a person who is experienced in the care and management of crime victims, such as an emergency department doctor or nurse or a sexual assault nurse examiner.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AFTER SEXUAL ASSAULT",
"     </span>",
"    </p>",
"    <p>",
"     After being sexually assaulted, you may have a lot of questions, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Why did this happen to me?",
"      </li>",
"      <li>",
"       Could I have prevented this?",
"      </li>",
"      <li>",
"       Will I develop an infection or become pregnant as a result of the assault?",
"      </li>",
"      <li>",
"       Who should I call first?",
"      </li>",
"      <li>",
"       Should I report this to the police?",
"      </li>",
"      <li>",
"       Is this reportable?",
"      </li>",
"      <li>",
"       Since I was drinking, isn't this my fault?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In all cases, it is important to know that you did not cause the sexual assault. Sexual assault is an act of violence, intimidation, and control. No one ever \"deserves\" to be assaulted, even if you wore tight clothing or initially showed interest in your assailant. You cannot consent to sex if you are under the influence of alcohol or drugs.",
"    </p>",
"    <p>",
"     The following steps are recommended after sexual assault:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Find a safe environment away from the assailant",
"      </li>",
"      <li>",
"       Call a close friend or relative &ndash; someone who will offer unconditional support",
"      </li>",
"      <li>",
"       Seek medical care; do not change clothes, bathe, douche, or brush your teeth until evidence is collected. A complete medical evaluation includes evidence collection, a physical examination, treatment",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       counseling. You do not have to do any part of this evaluation that you do not want to do.",
"      </li>",
"      <li>",
"       Discuss filing a police report with a crisis counselor, experienced social worker, sexual assault nurse examiner, or healthcare provider.",
"      </li>",
"      <li>",
"       Follow-up with a healthcare provider one to two weeks later",
"      </li>",
"      <li>",
"       Seek counseling services",
"      </li>",
"      <li>",
"       Inquire about victim compensation services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should seek medical care, even if some time has elapsed since the event or there is scant or no evidence for collection. A healthcare provider can offer advice on reporting the event, address concerns regarding infection, pregnancy, and safety, and help you to begin to recover.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SEEK MEDICAL CARE",
"     </span>",
"    </p>",
"    <p>",
"     It is important to seek emergency medical care as soon as possible to begin coping with the complex emotional issues surrounding rape. Medical care is usually provided by a doctor",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a sexual assault nurse examiner (SANE) in a hospital emergency department or medical clinic. Evidence collection may occur up to 120 hours from the assault and occurs with the consent of the patient.",
"    </p>",
"    <p>",
"     A sexual assault nurse examiner is a specially trained and certified professional who will provide needed care, document the details of the assault, and collect evidence. The nurse can recommend treatment for sexually transmitted infections and pregnancy prevention if needed. In addition, the nurse is available to testify in court [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     To locate a center that provides medical care after rape, call a local or national sexual assault hotline, available in the United States by calling 1-800-656-4673 (HOPE). Some hotlines offer a trained crisis counselor to accompany you to the hospital; alternately, a supportive friend or family member can go with you.",
"    </p>",
"    <p>",
"     If the local hospital does not have access to a crisis counselor or sexual assault nurse examiner, ask your physician to collect evidence as part of the physical examination. Laboratory testing may also be needed. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Laboratory testing'",
"     </a>",
"     below and",
"     <a class=\"local\" href=\"#H6\">",
"      'Physical examination'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Reporting sexual assault to the police",
"     </span>",
"     &nbsp;&mdash;&nbsp;Only 16 to 38 percent of rape victims report the rape to law enforcement, and only 17 to 43 percent present for medical evaluation after rape; one-third of victims of rape never report the assault to their primary care doctor [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/3,7\">",
"      3,7",
"     </a>",
"     ]. For this reason, all victims are encouraged to provide a detailed description of events and allow a thorough physical examination.",
"    </p>",
"    <p>",
"     In most states, evidence may be collected without reporting to the police. The best chance of collecting accurate information and evidence is within the first 24 hours of the sexual assault, although some states allow evidence to be collected up to five days later. Changing clothes, showering or bathing, eating, douching, going to the bathroom, and brushing your hair or teeth should be delayed until evidence is collected, if possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      History of events",
"     </span>",
"     &nbsp;&mdash;&nbsp;Care after sexual assault includes talking with a clinician about what occurred before, during, and after the incident, and describing the assailant(s). A sexual assault nurse examiner or another healthcare provider usually conducts this interview with you privately, without family member or friends. After the interview, a physical examination with or without evidence collection may be done.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;During a physical examination, a healthcare provider will document any cuts or bruises on your body. The most commonly injured areas include the breasts, external genitals, vagina, anus, and rectum; these areas will be carefully examined, swabbed, and cultured. With your permission, these areas may be photographed. A friend, family member, or crisis counselor may be present during the physical examination if you wish.",
"    </p>",
"    <p>",
"     In addition, fingernail scrapings and clippings, pubic and head hair samples, and blood and saliva samples are usually obtained. These samples are labeled, packaged, and sealed, along with your clothing and any other evidence, in an evidence collection kit. This kit must be given directly to a police officer or stored in a secure and locked location to ensure that no one tampers with this evidence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Preventive treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a small risk of becoming infected or pregnant as a result of sexual assault. The risk that a woman will become infected with HIV after a single episode of consensual vaginal intercourse (not sexual assault) with an HIV infected man is estimated at 0.1 percent, and from a single episode of consensual anal intercourse at 2 percent. The risk of developing HIV from a sexual assault may be higher, especially if your skin is torn or cut, if there was bleeding, or if there were multiple assailants.",
"    </p>",
"    <p>",
"     The Centers for Disease Control and Prevention (CDC) and other expert groups recommend preventive treatment if your mouth, vagina, anus, or non-intact skin (eg, a cut) was exposed to the assailant's blood or bodily fluids.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preventive treatment for gonorrhea, chlamydia, and trichomonas usually includes three antibiotics. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"        \"Patient information: Gonorrhea (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"        \"Patient information: Chlamydia (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Preventive treatment for hepatitis B may not be needed if you were previously vaccinated with the full series of three hepatitis B vaccines. If you were not previously vaccinated with hepatitis B vaccine, one dose is given immediately, followed by additional doses one and six months later. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"        \"Patient information: Hepatitis B (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Preventive treatment for HIV may be recommended if you are evaluated within 72 hours of being assaulted. A healthcare provider will discuss the potential risks and benefits of preventive HIV treatments. Preventive treatments for HIV are not usually recommended if more than 72 hours have passed since the assault. Most emergency departments will provide five days of preventive medication; you are then encouraged to follow-up with a healthcare provider who specializes in the treatment of infectious diseases. See the Center for Disease Control Web site:",
"       <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm\">",
"        www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       If you are female and are seen within five days (120 hours) after sexual assault, ask about medication to reduce your risk of becoming pregnant. The treatment usually includes one dose of a hormone, which is specifically designed to reduce the risk of pregnancy. This treatment does not induce abortion and will not end a pregnancy. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"        \"Patient information: Emergency contraception (morning after pill) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you seek care five or more days after being assaulted, you may consider having a copper intrauterine device (IUD) placed to prevent pregnancy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      \"Patient information: Emergency contraception (morning after pill) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Laboratory testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testing for chlamydia, gonorrhea, trichomonas, hepatitis B, and HIV is recommended if you have signs or symptoms of one of these infections. However, testing for these infections in the days following the acute assault will only confirm prior infection, not an infection as a result of the assault.",
"    </p>",
"    <p>",
"     If you are tested for sexually transmitted infections during the evaluation, it is important to understand that the results will become part of your medical record and will be available to the assailant's attorney if the case goes to trial. Thus, the information could potentially be used to discredit you. For these reasons, some victims choose to avoid STI testing at this time and receive prophylactic treatment for STI&rsquo;s. To locate a clinic that provides anonymous HIV testing in the United States, call 1-800-CDC-INFO (1-800-232-4636). &nbsp;",
"    </p>",
"    <p>",
"     If you are female, you may have a blood or urine pregnancy test during your evaluation; testing within five days after sexual assault can tell if you were pregnant at the time of the assault, but does not indicate if you will become pregnant as a result of the assault. The risk of becoming pregnant after assault depends upon several factors, including the timing of your menstrual cycle (",
"     <a class=\"graphic graphic_table graphicRef71494 \" href=\"UTD.htm?0/20/331\">",
"      table 1",
"     </a>",
"     ). A pregnancy test is recommended at the follow-up visit to determine if you became pregnant as a result of the rape. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Follow-up care'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     A blood and urine test to test for drugs (eg, Rohypnol or GHB, benzodiazepines) that can affect your level of consciousness are recommended if you have difficulty remembering events during or after the assault. However, it is important for you to understand that these tests can also provide evidence of drug or alcohol use. The assailant's attorney will have access to these results, and could potentially use this information to discredit you. Discuss the risks and benefits of drug testing with an experienced healthcare provider or sexual assault counselor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      FOLLOW-UP CARE",
"     </span>",
"    </p>",
"    <p>",
"     Most experts recommend that you have a follow-up visit with a healthcare provider within two weeks of the assault. At this visit, you can have follow-up testing, get treatment if needed, and discuss how you are recovering.",
"    </p>",
"    <p>",
"     Testing for gonorrhea and chlamydia does not need to be repeated if you took preventive antibiotic treatments. Testing for gonorrhea, chlamydia, trichomonas, and bacterial vaginosis may be recommended after the assault if you did not take preventive treatments at the initial evaluation. Testing is also recommended if you develop symptoms of an infection or would like to be tested. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"      \"Patient information: Symptoms of HIV infection (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Testing for pregnancy is recommended four weeks after the initial examination if you took an emergency contraceptive pill. If you did not use this treatment and you do not have your menstrual period on time, a pregnancy test is recommended.",
"    </p>",
"    <p>",
"     Testing for HIV is usually repeated at six weeks, three months, and six months after the assault. This schedule of testing is recommended because, in some cases, it takes up to six months for the blood test to become positive. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"      \"Patient information: Testing for HIV (Beyond the Basics)\"",
"     </a>",
"     .).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Protecting others",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are exposed to blood or bodily fluids during an assault, you must understand the importance of preventing the spread of any potential infection to others (for example, sexual partner(s)) during the follow-up period. These measures are especially important during the first three months after exposure. &nbsp;",
"    </p>",
"    <p>",
"     During this time, you should use a condom with any sexual activity to reduce the risk of transmitting the potential infection to your partner. Condoms reduce, but do not completely eliminate, the chances of transmitting hepatitis and HIV infection to others. Women should avoid becoming pregnant for three months. Donations of blood, plasma, organs, tissue, or semen are not recommended during the first three months.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      EMOTIONAL SUPPORT",
"     </span>",
"    </p>",
"    <p>",
"     Sexual assault victims often need extensive emotional support. Symptoms of anger, fear, anxiety, physical pain, sleep disturbance, lack of appetite, shame, guilt, depression, and intrusive thoughts can develop in the days to weeks following the assault. Many victims are reluctant to seek help because of their fear that thinking or talking about their experience will be too painful. However, most victims find counseling helpful in the process of recovering and moving on with their life.",
"    </p>",
"    <p>",
"     In the weeks after an assault, some victims develop physical and emotional symptoms, such as pain in the muscles, joints, genitals, pelvis",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     abdomen, lack of appetite, difficulty sleeping, or nightmares. Some victims find it very difficult to resume their habits, lifestyles, and sexual relationships. This collection of symptoms is called the rape trauma syndrome; this can last several months.",
"    </p>",
"    <p>",
"     A number of treatment options can help you to cope with the complicated emotional issues surrounding sexual trauma. Early treatment may help to reduce your risk of long-term problems with depression, anxiety, or posttraumatic stress disorder. Crisis centers such as the Rape, Abuse, &amp; Incest National Network (",
"     <a class=\"external\" href=\"file://www.rainn.org/\">",
"      www.rainn.org",
"     </a>",
"     or 1-800-656-HOPE (4673)) can help you to obtain information about resources and qualified providers in your area.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Counseling or psychotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Counseling or psychotherapy can be helpful in dealing with the events of the assault itself as well as the anger, fear, depression, or anxiety that many people feel afterwards.",
"    </p>",
"    <p>",
"     Several types of healthcare providers provide counseling, including social workers, psychologists, nurses, and psychiatrists. Some people prefer to meet one-on-one with a counselor while others prefer to meet in a group setting with other people who have had similar experiences.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antidepressant",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     antianxiety medications may be recommended if you have emotional or psychological problems that are severe or do not improve with counseling alone. Medication can help to manage the following symptoms:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Intrusive thoughts, nightmares, and flashbacks",
"      </li>",
"      <li>",
"       Feeling jumpy or startling easily at sudden noise",
"      </li>",
"      <li>",
"       Remaining \"on guard\" or constantly alert",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A class of antidepressant medications called selective serotonin reuptake inhibitors (SSRIs) are often recommended first. Medications in this class include fluoxetine (Prozac&reg;), sertraline (Zoloft&reg;), paroxetine (Paxil&reg;), citalopram (Celexa&reg;), fluvoxamine (Luvox&reg;) and escitalopram (Lexapro&reg;). These medications may be prescribed by an internist, family physician, or other healthcare provider. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In most cases, the antidepressant medication is continued for 6 to 12 months. When you stop an antidepressant, you should taper the dose over two to four weeks to minimize medication withdrawal symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      LEGAL ISSUES",
"     </span>",
"    </p>",
"    <p>",
"     The procedures for reporting and prosecuting sexual assault and collecting evidence vary by state. In the United States, sexual assaults that involve children under 16 or 18 years or elderly people must be reported. Some states require reporting of any and all sexual assaults. In some states, victims are not required to file a police report immediately, while in other states, an evidence kit will not be collected unless the police are notified.",
"    </p>",
"    <p>",
"     Many states have witness assistance programs that can provide advice on the pros and cons of reporting sexual assault, assistance in navigating the legal system, and financial compensation for the victim.",
"    </p>",
"    <p>",
"     Information about individual state laws is available online at the United States Department of Justice Office of Violence Against Women website: (",
"     <a class=\"external\" href=\"file://www.usdoj.gov/ovw/\">",
"      www.usdoj.gov/ovw/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804365466\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142246\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=see_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142273\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=see_link\">",
"      Differential diagnosis of suspected child abuse",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11510?source=see_link\">",
"      Management and sequelae of sexual abuse in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information [",
"     <a class=\"abstract\" href=\"UTD.htm?1/30/1509/abstract/1,8-11\">",
"      1,8-11",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Department of Justice Office of Violence Against Women",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.usdoj.gov/ovw/\">",
"        www.usdoj.gov/ovw/",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.womenshealth.gov/violence-against-women/get-help-for-violence/resources-by-state-violence-against-women.cfm\">",
"        file://www.womenshealth.gov/violence-against-women/get-help-for-violence/resources-by-state-violence-against-women.cfm",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Centers for Disease Control",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.cdc.gov/violenceprevention/sexualviolence/index.html\">",
"        www.cdc.gov/violenceprevention/sexualviolence/index.html",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Center for Victims of Crime",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.ncvc.org/ncvc/Main.aspx\">",
"        www.ncvc.org/ncvc/Main.aspx",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Rape, Abuse, &amp; Incest National Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.rainn.org/\">",
"        www.rainn.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       1-800-656-HOPE (4673)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/30/1509?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/1\">",
"      Koss MP. The women's mental health research agenda. Violence against women. Am Psychol 1990; 45:374.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Victims of Crime and Crime Victims Research and Treatment Center. Rape in America: A Report to the Nation. Arlington, VA, 1992.",
"    </li>",
"    <li>",
"     Tjaden PG, Thoennes N. Extent, nature, and consequences of rape victimization: Findings from the National Violence Against Women Survey. Publication no. NCJ210346, National Institute of Justice, Washington, DC, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/4\">",
"      Krebs CP, Lindquist CH, Warner TD, et al. College women's experiences with physically forced, alcohol- or other drug-enabled, and drug-facilitated sexual assault before and since entering college. J Am Coll Health 2009; 57:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/5\">",
"      Lawyer S, Resnick H, Bakanic V, et al. Forcible, drug-facilitated, and incapacitated rape and sexual assault among undergraduate women. J Am Coll Health 2010; 58:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/6\">",
"      Linden JA. Clinical practice. Care of the adult patient after sexual assault. N Engl J Med 2011; 365:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/7\">",
"      Feldhaus KM, Houry D, Kaminsky R. Lifetime sexual assault prevalence rates and reporting practices in an emergency department population. Ann Emerg Med 2000; 36:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/8\">",
"      Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/9\">",
"      Wiley J, Sugar N, Fine D, Eckert LO. Legal outcomes of sexual assault. Am J Obstet Gynecol 2003; 188:1638.",
"     </a>",
"    </li>",
"    <li>",
"     A National Protocol for Sexual Assault Medical Forensic Examination Adults/Adolescents. Available at www.ncjrs.gov/pdffiles1/ovw/206554.pdf www.ncjrs.gov/pdffiles1/ovw/206554.pdf (Accessed on December 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1509/abstract/11\">",
"      Lewis-O'Connor A, Franz H, Zuniga L. Limitations of the national protocol for sexual assault medical forensic examinations. J Emerg Nurs 2005; 31:267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_30_1509=[""].join("\n");
var outline_f1_30_1509=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AFTER SEXUAL ASSAULT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SEEK MEDICAL CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           FOLLOW-UP CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           EMOTIONAL SUPPORT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           LEGAL ISSUES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?0/20/331\" title=\"table 1\">",
"           Chance of pregnancy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1510="Linezolid: Patient drug information";
var content_f1_30_1510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Linezolid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     see \"Linezolid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     see \"Linezolid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zyvox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zyvoxam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Linezolid may cause anemia, low white blood cell counts, low platelet counts, or may lower all cells made in the bone marrow. Blood tests will be done each week while on this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to linezolid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Citalopram, fluvoxamine, paroxetine, or sertraline. Do not use within 2 weeks of other antidepressants.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid eating foods like aged cheeses and meats, soy sauce, soy beans, Miso soup, Italian green beans (fava beans), snowpea or broad bean pods, sauerkraut, kimchee, yeast extracts (Marmite), red or white wine, and beer including alcohol-free beer. Very bad side effects may happen. Ask your doctor for a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped, follow diet for at least 2 more weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Gently mix before use. Do not shake.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699464",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 3 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10808 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1510=[""].join("\n");
var outline_f1_30_1510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188967\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021692\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021694\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021693\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021698\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021699\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021701\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021696\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021697\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021702\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021703\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=related_link\">",
"      Linezolid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=related_link\">",
"      Linezolid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1511="Pediculosis pubis and pediculosis ciliaris";
var content_f1_30_1511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediculosis pubis and pediculosis ciliaris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1511/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/30/1511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediculosis pubis, pediculosis corporis, and pediculosis capitis are disorders caused by infestation by one of three varieties of lice that specifically infest humans (",
"    <a class=\"graphic graphic_figure graphicRef52420 \" href=\"UTD.htm?4/8/4226\">",
"     figure 1",
"    </a>",
"    ). Pediculosis pubis is usually sexually transmitted, and can extend beyond the pubic area to involve other areas of the body, including the eyelashes (pediculosis ciliaris). Phthirus pubis, also known as the crab louse, is the responsible organism.",
"   </p>",
"   <p>",
"    The clinical findings, diagnosis, and treatment of pediculosis pubis and pediculosis ciliaris will be reviewed here. Pediculosis capitis and pediculosis corporis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link\">",
"     \"Pediculosis capitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=see_link\">",
"     \"Pediculosis corporis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PEDICULOSIS PUBIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Phthirus pubis",
"    </em>",
"    , the crab louse, is usually transmitted during sexual contact, and increasing sexual freedom in many societies has contributed to its spread. Teenagers and young adults are most commonly affected.",
"   </p>",
"   <p>",
"    Transmission via contact with fomites such as clothing, towels, or linen may also occur, but is thought to be less common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Phthirus pubis gravitates toward warm environments and is not adapted to crawling on smooth surfaces, making infestation from a toilet seat unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thorough sexual history and screening for other sexually transmitted diseases is warranted in patients with pediculosis pubis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a series of 121 individuals with pediculosis pubis, for example, 31 percent had another sexually transmitted disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phthirus pubis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crab louse is a rounded, stubby parasite, 0.8 to 1.2 mm long that is translucent and difficult to see unless filled with blood from a recent meal (",
"    <a class=\"graphic graphic_figure graphicRef52420 \" href=\"UTD.htm?4/8/4226\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71170 \" href=\"UTD.htm?4/6/4194\">",
"     picture 1",
"    </a>",
"    ). Four of its six legs terminate in prominent crab-like claws, which are suited to grasp and hold on tightly to pubic and other body hairs.",
"   </p>",
"   <p>",
"    The life span of the female is three to four weeks, during which time she lays a maximum of three eggs (nits) per day for a total of 26 or more. The eggs are cemented firmly to the base of a hair, where they incubate for six to eight days before hatching [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Itching is the chief complaint in adults, mainly in the pubic area, but also in the axillae. In hairy individuals, no hair-bearing area is immune to involvement. The scalp is spared in most cases, but is occasionally involved in individuals with thick, curly hair [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pale bluish 0.5 to 1 cm macules (maculae ceruleae) may develop in individuals with prolonged infestation, and are the result of injection of louse anticoagulant saliva during feeding. These lesions are usually found on the lower abdomen, proximal thighs, or buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ]. Inguinal lymphadenopathy is present in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pediculosis pubis is made by demonstration of the louse or nits (louse eggs) (",
"    <a class=\"graphic graphic_picture graphicRef55191 graphicRef58267 \" href=\"UTD.htm?6/45/6873\">",
"     picture 2A-B",
"    </a>",
"    ). The presence of nits can easily be confirmed on microscopic examination (",
"    <a class=\"graphic graphic_picture graphicRef51210 \" href=\"UTD.htm?21/62/22497\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once a diagnosis is made, it is important to evaluate the patient for other sexually transmitted diseases. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some disorders that also affect pubic and axillary areas can be confused with pediculosis pubis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichomycosis axillaris, a condition in which tan concretions composed of corynebacteria are found on hair shafts (",
"      <a class=\"graphic graphic_picture graphicRef64304 \" href=\"UTD.htm?34/57/35732\">",
"       picture 4",
"      </a>",
"      ). Corynebacterium are evident on gram stain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=see_link&amp;anchor=H17#H17\">",
"       \"Erythrasma\", section on 'Other cutaneous corynebacterium infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      White piedra, a fungal infection of the hair shaft characterized by white or tan adherent nodules, can occasionally can be mistaken for nits by the untrained eye (",
"      <a class=\"graphic graphic_picture graphicRef69898 \" href=\"UTD.htm?6/47/6904\">",
"       picture 5",
"      </a>",
"      ). Fungal hyphae can be seen on a potassium hydroxide (KOH) preparation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=see_link\">",
"       \"Infections due to Trichosporon species and Blastoschizomyces capitatus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"       \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scabies can present with pruritus and excoriations in the pubic area. However, the mites are not visible with the naked eye, and nits are absent (",
"      <a class=\"graphic graphic_picture graphicRef65362 \" href=\"UTD.htm?24/20/24900\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"       \"Scabies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical pediculicides are commonly prescribed for the treatment of pediculosis pubis. Treatment options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    and, less preferably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    . Data are limited on the efficacy of these therapies for pediculosis pubis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H7#H7\">",
"     \"Pediculosis capitis\", section on 'Topical pediculicides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin should be cool and dry before application of a topical pediculicide to minimize percutaneous absorption. Treatment should be applied to all areas of suspected involvement, which typically includes the pubic and perianal areas, thighs, trunk, and axillae [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/7\">",
"     7",
"    </a>",
"    ]. Nits can be removed with fingernails, a nit comb, or tweezers. Patients should put on clean underwear and clothing following treatment, and should abstain from sexual contact until they are reevaluated to rule out persistent infestation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the two first-line regimens recommended for pubic lice in the 2010 Sexually Transmitted Disease Treatment Guidelines from the United States Centers for Disease Control (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       Permethrin",
"      </a>",
"      1% cream rinse applied to the affected areas and washed off after 10 minutes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"       Pyrethrins",
"      </a>",
"      with piperonyl butoxide applied to the affected areas and washed off after 10 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although high cure rates following topical treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    with piperonyl butoxide plus nit combing were reported in a small trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/10\">",
"     10",
"    </a>",
"    ], a single pediculicide treatment may not eradicate the infestation in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. One small, unblinded randomized trial that compared treatment with a single application of 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    with a single application of 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    (both in combination with nit combing) found that ten days following treatment, persistent infestation was detected in 43 and 40 percent of subjects, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H12#H12\">",
"     \"Pediculosis capitis\", section on 'Lindane toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rediscovery of louse infestation after treatment may result from a failure of the treatment to eradicate all viable lice and eggs or from reexposure to",
"    <em>",
"     Phthirus pubis",
"    </em>",
"    . Recommendations for follow-up after an initial treatment vary. The CDC recommends treating with a pediculicide plus nit combing, reevaluating patients after 9 to 10 days, and retreating at that time if lice are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast to the CDC, 2010 European guidelines and some authors recommended routinely retreating [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the CDC recommendation to reevaluate patients after 9 to 10 days prior to retreatment, but instruct patients who will not be able to receive a follow-up clinical examination at that time to proceed with a second treatment. Since the typical incubation period for louse eggs is six to eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ], at least one week should elapse prior to retreatment. We advise patients to reapply the drug after 9 to 10 days to kill any lice that have hatched from eggs that survived the initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative regimens to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    with piperonyl butoxide include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"       Malathion",
"      </a>",
"      0.5% lotion applied to the affected areas and washed off after 8 to 12 hours. The long application time, poor odor, and potential flammability of malathion make this therapy less preferable for some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H9#H9\">",
"       \"Pediculosis capitis\", section on 'Malathion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      250",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      orally, repeated in two weeks. Clinical studies examining the efficacy of oral ivermectin for the treatment of pediculosis pubis are not available. However, clinicians have reported success with this therapy in clinical practice, and have suggested that treatments separated by only one week may also be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/12\">",
"       12",
"      </a>",
"      ]. Ivermectin should",
"      <strong>",
"       not",
"      </strong>",
"      be used in pregnant or lactating women; in addition, there are not adequate safety data for ivermectin in children weighing less than 15 kg [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9,13\">",
"       9,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     Lindane",
"    </a>",
"    is not recommended as a first-line treatment for pediculosis pubis because of the drug&rsquo;s adverse effect profile. Benzyl alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17267?source=see_link\">",
"     spinosad",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , effective and generally well-tolerated therapies for pediculosis capitis, have not been evaluated for the treatment of pediculosis pubis. &nbsp; (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H12#H12\">",
"     \"Pediculosis capitis\", section on 'Lindane toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H7#H7\">",
"     \"Pediculosis capitis\", section on 'Topical pediculicides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance of lice to topical pediculicides has become a significant problem in the treatment of pediculosis capitis. In contrast, reports of resistance of Phthirus pubis to pediculicides are almost nonexistent. A case in which pubic lice were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    in vitro but were eradicated from the source patient with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    5% cream has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/14\">",
"     14",
"    </a>",
"    ]. It is unclear whether the resistance will emerge in the future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link&amp;anchor=H15#H15\">",
"     \"Pediculosis capitis\", section on 'Pediculicide resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Household members and fabrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual partners should be treated at the same time as the patient to prevent cross reinfection. Non-sexual household contacts do",
"    <strong>",
"     not",
"    </strong>",
"    need to be treated if they have no signs of infestation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bedding and clothing should be machine washed in hot water and dried in a hot dryer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. Temperatures should reach at least 130&ordm;F. Dry cleaning is also effective.",
"   </p>",
"   <p>",
"    If clothing or bedding cannot be washed or dry cleaned, placing it in a sealed plastic bag is an option. Crawling lice die within 48 hours after removal from the host; items that cannot be cleaned should be bagged or removed from body contact for at least 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9\">",
"     9",
"    </a>",
"    ]. Bagging items for two weeks may eliminate the possibility of reinfestation from newly hatched lice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/16\">",
"     16",
"    </a>",
"    ]. Fumigation of living areas is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PEDICULOSIS CILIARIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to infesting the pubic area, the crab louse (Phthirus pubis) can infest other hair-bearing areas. As an example, eyelash infestation can occur in adolescents or adults with pediculosis pubis or as isolated involvement in children who are close contacts of adults with the infestation. The term pediculosis ciliaris (also called phthiriasis palpebrarum) is used to describe this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected individuals may complain of itching, burning, and eye irritation. Children with pediculosis ciliaris may continually rub their eyes.",
"   </p>",
"   <p>",
"    There is reddish crusting and matting of the lashes, and an associated conjunctivitis is common. Involvement is usually bilateral. On close inspection, translucent nits (louse eggs) approximately 0.5 mm in length are visualized at the eyelash base (",
"    <a class=\"graphic graphic_picture graphicRef60762 \" href=\"UTD.htm?29/57/30613\">",
"     picture 7",
"    </a>",
"    ). If careful examination to look for the presence of nits is not performed, the disorder may be mistaken for bacterial conjunctivitis, allergic contact dermatitis, or blepharitis associated with seborrheic dermatitis or rosacea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preauricular and submental nodes may be enlarged. Involvement of eyebrows may also occur in children, and in very young children, a few lice are occasionally found clinging to hairs at the periphery of the scalp.",
"   </p>",
"   <p>",
"    Close contact with non-genital sites of infestation on an adult or shared household fomites (eg, bedding, towels, clothing) are the sources of pediculosis ciliaris in most cases of infestation in children. However, pediculosis ciliaris in children may be a sign of sexual abuse, and the possibility of abuse should be investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the eyelash involvement, treatment for pediculosis ciliaris must be modified to protect the eyes. Initial therapy is aimed at mechanically dislodging the lice and nits after twice daily application of ordinary petrolatum or an occlusive ophthalmic ointment to the eyelid margins for 8 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Secondary pyoderma and conjunctivitis can be managed in most instances by ophthalmic topical antibiotic preparations.",
"   </p>",
"   <p>",
"    Medications aimed at the infestation may be considered in patients who do not respond to mechanical dislodgment. Data are limited to case series and there are no studies comparing the efficacy of different treatments for pediculosis ciliaris. Removal of the eyelashes is a possible alternative to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (two doses of 200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    by mouth given one week apart) was effective in a case series of four patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/13\">",
"     13",
"    </a>",
"    ]. The same cautions about ivermectin use discussed above apply to the treatment of pediculosis ciliaris. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Successful therapy with twice daily application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    4% gel has been reported in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/20\">",
"     20",
"    </a>",
"    ]. The mechanism of action is unclear, but may involve a neurotoxic effect on lice or pediculicidal action via another pathway.",
"   </p>",
"   <p>",
"    Other treatments have been reported to be successful in small numbers of patients. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    20% drops [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/21\">",
"     21",
"    </a>",
"    ], yellow mercuric oxide ointment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/22\">",
"     22",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    1% cream rinse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/23\">",
"     23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    1% lotion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    1% shampoo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/26\">",
"     26",
"    </a>",
"    ]. The potential for irritation or ocular damage should be considered before employing any of these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1511/abstract/16,24,27,28\">",
"     16,24,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/5/43089?source=see_link\">",
"       \"Patient information: Lice (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/44/16065?source=see_link\">",
"       \"Patient information: Head lice (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=see_link\">",
"       \"Patient information: Pubic lice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediculosis pubis is primarily transmitted via sexual contact. Patients often present with pubic and axillary pruritus. The diagnosis is made through the visual identification of lice and nits. Individuals with pediculosis pubis should be screened for other sexually transmitted diseases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pediculosis pubis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediculosis pubis is treated with topical pediculicides. Based upon safety and ease of use, we suggest treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      1% or a product containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/9/12436?source=see_link\">",
"       pyrethrins",
"      </a>",
"      with piperonyl butoxide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should be repeated after 9 to 10 days if lice remain. Sexual partners should be treated simultaneously. Bedding and clothing should be laundered in hot water. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pediculosis pubis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infestation of the eyelashes may occur in individuals with pediculosis pubis or in children who are in close contact with infested individuals. Although the majority of children with this diagnosis acquire the infestation via non-sexual contact, the possibility of sexual abuse should be considered. Due to the relative safety of these therapies, we suggest treatment with topical petrolatum or an occlusive ophthalmic ointment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pediculosis ciliaris'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/1\">",
"      Galiczynski EM Jr, Elston DM. What's eating you? Pubic lice (Pthirus pubis). Cutis 2008; 81:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/2\">",
"      Leone PA. Scabies and pediculosis pubis: an update of treatment regimens and general review. Clin Infect Dis 2007; 44 Suppl 3:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/3\">",
"      Chapel TA, Katta T, Kuszmar T, DeGiusti D. Pediculosis pubis in a clinic for treatment of sexually transmitted diseases. Sex Transm Dis 1979; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/4\">",
"      Pierzchalski JL, Bretl DA, Matson SC. Phthirus pubis as a predictor for chlamydia infections in adolescents. Sex Transm Dis 2002; 29:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/5\">",
"      Kalter DC, Sperber J, Rosen T, Matarasso S. Treatment of pediculosis pubis. Clinical comparison of efficacy and tolerance of 1% lindane shampoo vs 1% permethrin creme rinse. Arch Dermatol 1987; 123:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/6\">",
"      Ragheb DA, Morsy TA, Abdalla HM, Abou Gamra MM. In vitro control of Phthirus pubis with four pediculocides: Eurax, Elimite, Licid and Benzanil. J Egypt Soc Parasitol 1995; 25:677.",
"     </a>",
"    </li>",
"    <li>",
"     Stone SP, Goldfarb JN, Bacelieri RE. Scabies, other mites, and pediculosis. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolf K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. p.2029.",
"    </li>",
"    <li>",
"     file://www.cdc.gov/parasites/lice/pubic/treatment.html (Accessed on January 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/9\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/10\">",
"      Newsom JH, Fiore JL Jr, Hackett E. Treatment of infestation with Phthirus pubis: comparative efficacies of synergized pyrethrins and gamma-benzene hexachloride. Sex Transm Dis 1979; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/11\">",
"      Scott GR, Chosidow O, IUSTI/WHO. European guideline for the management of pediculosis pubis, 2010. Int J STD AIDS 2011; 22:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/12\">",
"      Burkhart CG, Burkhart CN. Oral ivermectin for Phthirus pubis. J Am Acad Dermatol 2004; 51:1037; author reply 1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/13\">",
"      Burkhart CN, Burkhart CG. Oral ivermectin therapy for phthiriasis palpebrum. Arch Ophthalmol 2000; 118:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/14\">",
"      Speare R, Koehler JM. A case of pubic lice resistant to pyrethrins. Aust Fam Physician 2001; 30:572.",
"     </a>",
"    </li>",
"    <li>",
"     Pubic \"crab\" lice. Centers for Disease Control and Prevention. www.cdc.gov/lice/pubic/index.html. (Accessed on January 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/16\">",
"      Pinckney J 2nd, Cole P, Vadapalli SP, Rosen T. Phthiriasis palpebrarum: a common culprit with uncommon presentation. Dermatol Online J 2008; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/17\">",
"      Orkin M, Epstein E, Maibach HI. Treatment of today's scabies and pediculosis. JAMA 1976; 236:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/18\">",
"      Yoon KC, Park HY, Seo MS, Park YG. Mechanical treatment of phthiriasis palpebrarum. Korean J Ophthalmol 2003; 17:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/19\">",
"      Ikeda N, Nomoto H, Hayasaka S, Nagaki Y. Phthirus pubis infestation of the eyelashes and scalp hairs in a girl. Pediatr Dermatol 2003; 20:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/20\">",
"      Kumar N, Dong B, Jenkins C. Pubic lice effectively treated with Pilogel. Eye (Lond) 2003; 17:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/21\">",
"      Mathew M, D'Souza P, Mehta DK. A new treatment of pthiriasis palpebrarum. Ann Ophthalmol 1982; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/22\">",
"      Ashkenazi I, Desatnik HR, Abraham FA. Yellow mercuric oxide: a treatment of choice for phthiriasis palpebrarum. Br J Ophthalmol 1991; 75:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/23\">",
"      Klaus S, Shvil Y, Mumcuoglu KY. Generalized infestation of a 3 1/2-year-old girl with the pubic louse. Pediatr Dermatol 1994; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/24\">",
"      Kincaid MC. Phthirus pubis infestation of the lashes. JAMA 1983; 249:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/25\">",
"      Burns DA. The treatment of Pthirus pubis infestation of the eyelashes. Br J Dermatol 1987; 117:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/26\">",
"      Rundle PA, Hughes DS. Phthirus pubis infestation of the eyelids. Br J Ophthalmol 1993; 77:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/27\">",
"      Raoult D, Roux V. The body louse as a vector of reemerging human diseases. Clin Infect Dis 1999; 29:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1511/abstract/28\">",
"      Pe'er J, BenEzra D. Corneal damage following the use of the pediculocide A-200 Pyrinate. Arch Ophthalmol 1988; 106:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4037 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AD25BEE436-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1511=[""].join("\n");
var outline_f1_30_1511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PEDICULOSIS PUBIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phthirus pubis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Household members and fabrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PEDICULOSIS CILIARIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4037|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/8/4226\" title=\"figure 1\">",
"      Types of lice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4037|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/6/4194\" title=\"picture 1\">",
"      Pediculosis pubis louse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/21/35158\" title=\"picture 2A\">",
"      Pediculosis pubis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/36/7745\" title=\"picture 2B\">",
"      Pediculosis pubis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/62/22497\" title=\"picture 3\">",
"      Pediculosis pubis nits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/57/35732\" title=\"picture 4\">",
"      Trichomycosis axillaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/47/6904\" title=\"picture 5\">",
"      White piedra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/20/24900\" title=\"picture 6\">",
"      Scabies male genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/57/30613\" title=\"picture 7\">",
"      Pediculosis ciliaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=related_link\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=related_link\">",
"      Infections due to Trichosporon species and Blastoschizomyces capitatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/44/16065?source=related_link\">",
"      Patient information: Head lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/5/43089?source=related_link\">",
"      Patient information: Lice (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=related_link\">",
"      Patient information: Pubic lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=related_link\">",
"      Pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24339?source=related_link\">",
"      Pediculosis corporis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1512="Oncoplastic techniques in breast conserving surgery";
var content_f1_30_1512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oncoplastic techniques in breast conserving surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Benjamin Anderson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Kristine Calhoun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1512/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/30/1512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14027005\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncoplastic surgery merges the principles of oncology and plastic surgery, utilizing breast-flap advancement to address tissue defects and improve cosmesis from breast conserving surgery (BCS). BCS followed by radiation treatment comprises breast conserving therapy (BCT). The goals of BCT are to provide the survival equivalent of mastectomy, a cosmetically acceptable breast, and a low rate of recurrence in the treated breast.",
"   </p>",
"   <p>",
"    BCT is appropriate for most women with early stage breast cancer although there are clear contraindications to it, such as multicentric disease and persistently positive surgical resection margins. For breast conservation to be maximally effective, the cancer must be resected with adequate surgical margins while simultaneously maintaining the breast&rsquo;s shape and appearance.",
"   </p>",
"   <p>",
"    This review will present oncoplastic techniques for breast conservation. The management of early stage breast cancer and the major issues related to breast conservation techniques for surgical treatment of invasive breast cancer are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101093166\">",
"    <span class=\"h1\">",
"     ADVANTAGES OF ONCOPLASTIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncoplastic surgical techniques provide for breast conserving surgery (BCS) of the cancer with wide surgical margins while preserving the shape and appearance of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/1\">",
"     1",
"    </a>",
"    ]. In the clinical settings of BCS where the breast size in relation to the size of the cancer resected is adequate, the need to obliterate the cavity or re-orient the closure to avoid breast deformity is typically not necessary. However, oncoplastic procedures that include the advancement of breast tissue and obliteration of the cavity can facilitate cosmetic reshaping of the breast contour without creating skin dimpling or marked deformity.",
"   </p>",
"   <p>",
"    Clinical settings where oncoplastic techniques can improve cosmesis following BCS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer resection is large in relation to the size of the breast. Deformity of the breast contour, including dimpling of the skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      displacement of the nipple-areolar complex may occur with a conventional approach to obliterating the large cavity.",
"     </li>",
"     <li>",
"      Cancer location requires repositioning of the nipple-areolar complex (NAC) to maintain a natural breast appearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027026\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND PREOPERATIVE CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Selection criteria",
"      </strong>",
"      ��� Oncoplastic techniques are appropriate for most breast preservation candidates. The selection criteria for BCS and postoperative radiation therapy are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H8#H8\">",
"       \"Breast conserving therapy\", section on 'Selection criteria for BCT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"       \"Role of radiation therapy in breast conservation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tissue biopsy",
"      </strong>",
"      ��� Tissue biopsy of all suspicious areas of the breast, preferably using core needle sampling, should be performed and conclusive proof of malignancy should be documented. Every effort should be made to make the tissue diagnosis by needle sampling, to reduce unnecessary surgery and because an excisional biopsy scar may complicate the placement of the subsequent BCS incision. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"       \"Breast biopsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Imaging",
"      </strong>",
"      &mdash; Radiographic imaging (eg, MRI) may assist the surgeon to determine if the cancer can be resected with clean margins. An alternative approach for large cancers not amenable to BCS is the administration of neoadjuvant chemotherapy, which may decrease the size of the cancer and provide the opportunity for the patient to avoid a mastectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/2\">",
"       2",
"      </a>",
"      ]. Preoperative assessment of the extent of disease is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Assessing the extent of disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Multidisciplinary coordination",
"      </strong>",
"      ��� Once the diagnosis of cancer is made, multidisciplinary coordination facilitates treatment planning and streamlines patient care [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/3\">",
"       3",
"      </a>",
"      ]. For complex oncoplastic approaches, plastic surgery consultation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intraoperative collaboration should be arranged [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/4\">",
"       4",
"      </a>",
"      ]. Often the plastic surgeon will perform a contralateral breast lift or reduction to ensure breast symmetry at the same operative setting if it is highly likely the margins of resection will be clear of cancer. In the settings of uncertainty of margin status of BCS, a delay for any procedure of the contralateral breast is advised until the final pathology report is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"       \"Diagnostic evaluation of women with suspected breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"       \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Wire localization",
"      </strong>",
"      &mdash; For resection of nonpalpable lesions, preoperative wire localization by the radiologist allows accurate identification of the area requiring resection. The use of multiple wires can delineate the extent of the larger or segmentally distributed cancers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H15#H15\">",
"       \"Breast conserving therapy\", section on 'Margins of resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Evaluation of the axilla ���",
"      </strong>",
"      Evaluation of the axilla provides important information for treatment decisions in patients with invasive breast cancer. The management of the regional lymph nodes in breast cancer, sentinel node biopsy, and axillary dissection, are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"       \"Management of the regional lymph nodes in breast cancer\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      <strong>",
"       Skin marking",
"      </strong>",
"      &mdash; Skin landmarks should be marked preoperatively with the patient in the upright, sitting position for both breasts. These sites may be challenging to accurately locate once the patient is anesthetized and lying supine on the operating room table. Special attention should be given to scars from prior breast surgery, including the placement and location of breast implants.",
"     </li>",
"     <li>",
"      Relevant landmarks to be identified and marked include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The inframammary crease",
"     </li>",
"     <li>",
"      The anterior axillary fold at the pectoralis major muscle",
"     </li>",
"     <li>",
"      The posterior axillary fold of the latissimus dorsi muscle",
"     </li>",
"     <li>",
"      The sternal border of the breast",
"     </li>",
"     <li>",
"      The periareolar circle",
"     </li>",
"     <li>",
"      The superior border of the breast",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1075282222\">",
"    <span class=\"h1\">",
"     SURGEON&rsquo;S SAFETY CHECKLIST FOR ONCOPLASTIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid surgical complications, the breast surgeon should review and assess the patient&rsquo;s medical status. A preoperative checklist is a good way to assure that all safety issues have been addressed (",
"    <a class=\"graphic graphic_table graphicRef59666 \" href=\"UTD.htm?39/28/40395\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=see_link&amp;anchor=H697945#H697945\">",
"     \"Operating room safety\", section on 'Using a checklist for preoperative briefing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Informed consent",
"      </strong>",
"      &mdash; Informed consent should include a discussion of the risks, benefits, and alternatives of breast conserving surgery and any axillary surgery that is planned. The patient should be counseled regarding the risks of bleeding and infection, breast asymmetry, loss of sensation, seroma formation, fat necrosis, delayed healing, nipple necrosis, and the possibility of needing additional surgery for close or positive surgical margins. If concurrent axillary surgery is planned, the complications of sentinel node biopsy or axillary dissection should be discussed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of the regional lymph nodes in breast cancer\", section on 'Surgical complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Review films ���",
"      </strong>",
"      The patient&rsquo;s films should be reviewed with the radiologist and displayed in the operating room.",
"     </li>",
"     <li>",
"      <strong>",
"       Anesthesia",
"      </strong>",
"      &mdash; Oncoplastic surgery requires extensive mobilization and advancement of breast tissue, thus requiring general anesthesia. If concurrent axillary surgery is planned, the patient should",
"      <strong>",
"       not",
"      </strong>",
"      be paralyzed until the axillary portion of the surgery is completed so that testing of the large motor nerves during dissection is possible.",
"     </li>",
"     <li>",
"      <strong>",
"       Antibiotics",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      A preoperative antibiotic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , should be administered within an hour before making the incision [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. The efficacy of antibiotic prophylaxis decreases if administered more than one hour before surgery (",
"      <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A meta-analysis of the randomized controlled trials of preoperative antibiotics versus placebo in patients undergoing breast surgery found that the use of preoperative antibiotics was associated with a significant reduction in infection (relative risk = 0.60; CI 0.45-0.81) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Deep venous thrombosis prophylaxis",
"      </strong>",
"      &mdash;",
"      <strong>",
"      </strong>",
"      Primary prophylaxis for prevention of deep venous thrombosis should be employed (",
"      <a class=\"graphic graphic_table graphicRef50947 \" href=\"UTD.htm?34/54/35693\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027079\">",
"    <span class=\"h1\">",
"     ONCOPLASTIC TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of oncoplastic procedures is to resect the breast cancer with negative histologic margins and to preserve the contour of the breast. The general principles of the oncoplastic techniques include resecting a skin island with the fibroglandular tissue for large cancer resections, and advancing the deep fibroglandular tissues over the chest wall to obliterate a large resection defect.",
"   </p>",
"   <p>",
"    The most widely utilized oncoplastic techniques include some variation of a full-thickness resection of skin and fibroglandular tissue modeled after an elliptical or rhomboid resection commonly used for the removal of larger soft tissue skin lesions. Variants on oncoplastic resection techniques include the lateral segmentectomy, batwing mastopexy, central BCS, reduction mastopexy, and donut mastopexy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/4,13\">",
"     4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fibroglandular tissue of the breast has a rich anastomotic circulatory bed, which allows oncoplastic mastopexy and advancement of the breast tissue flaps to be performed with minimal threat to tissue viability. The well-collateralized breast vasculature allows the surgeon to remodel large amounts of breast tissue within the skin envelope without major risk of breast devascularization and subsequent necrosis. The axillary, intercostal, and internal mammary arteries primarily provide the arterial blood supply. By maintaining communication with one of these arterial connections, adequate blood supply to the breast parenchyma is maintained during cancer resection, tissue advancement, and mastopexy closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H370584485\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all oncoplastic techniques, the patient is positioned supine with her arms extended on arm boards at &le;90 degrees abduction from the chest wall. Arm positioning with &gt;90 degrees of abduction from the chest wall increases the potential for stretching the brachial plexus and should be avoided. It is important to position the arm while the patient is awake to make sure the arm is not abducted beyond what is comfortable for the patient, especially if there are preexisting problems with shoulder mobility. If a sentinel node biopsy or axillary dissection is also planned, the ipsilateral arm can be included in the prepped field at the discretion of the surgeon, allowing the arm to be mobilized during the procedure. The lateral chest wall should be positioned along the edge of the operating table.",
"   </p>",
"   <p>",
"    It is preferable to have both breasts prepped and draped into the field so that visual comparison with the patient in a sitting position is possible as the wound is closed. This positioning allows the surgeon to identify areas of unsightly tugging or dimpling inadvertently created during closure, so that they can be addressed at that time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H370584848\">",
"    <span class=\"h2\">",
"     Choice of technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of oncoplastic technique is based upon the location of the cancer in the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Superior pole or lateral cancers",
"      </strong>",
"      ��� For a superior pole or lateral breast cancer, a full-thickness fibroglandular resection including an overlying skin island with an advancement closure is the simplest and most commonly employed technique.",
"     </li>",
"     <li>",
"      <strong>",
"       Lower pole breast cancers ���",
"      </strong>",
"      For lower pole (inner and outer quadrant) breast cancers, including those at the three and nine o&rsquo;clock positions, a lateral segmentectomy or reduction mastopexy can be considered depending on the breast size. A lateral segmentectomy is more appropriate for a small breast, while a reduction mastopexy would be more appropriate for a larger breast.",
"     </li>",
"     <li>",
"      <strong>",
"       Centrally located cancers ���",
"      </strong>",
"      For a centrally located breast cancer and associated nipple involvement, a central BCS with removal of the nipple areolar complex provides an alternative to a mastectomy. However, central BCS procedures may result in an inadequate projection of smaller breasts and limit future options for reconstruction.",
"     </li>",
"     <li>",
"      <strong>",
"       Upper outer quadrant cancers",
"      </strong>",
"      ��� For segmentally distributed upper outer quadrant breast cancers, the donut mastopexy is the optimal technique. If the cancer is far removed from the nipple complex such that a donut incision would make dissection challenging, a parallelogram approach is preferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Upper inner quadrant cancers",
"    </strong>",
"    ��� For upper inner quadrant breast cancers, where the breast tissue is the thinnest, a simple re-approximation of breast tissue and skin without removal of the skin is performed. If a small skin island is included with the fibroglandular resection, superomedial displacement of the nipple-areolar complex (NAC) must be avoided to preserve breast symmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027088\">",
"    <span class=\"h3\">",
"     Parallelogram skin incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A straightforward method for planning the skin incision is to draw an outline of a parallelogram on the skin. An elongated ellipse or parallelogram incision is made that narrows and rounds the skin incision pattern to create two incisions of equal length that join in a tight &ldquo;V&rdquo; that on closure will minimize any degree of &ldquo;dog ear&rdquo; deformity at the corners. Removal of the overlying skin prevents skin dimpling or hollowing of the breast. The technique is illustrated in the figure (",
"    <a class=\"graphic graphic_picture graphicRef55176 \" href=\"UTD.htm?43/0/44040\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A rounded parallelogram with two equal length lines is drawn, thus marking the skin island to be excised in conjunction with the underlying target lesion and surrounding tissues. The surgeon should be cautious when designing the skin ellipse, because removal of too broad of an island can cause substantial shifting of the NAC.",
"   </p>",
"   <p>",
"    Flaps are then raised and the cancer is resected in standard fashion. Clips are placed and tissue advancement and closure are then performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284599171\">",
"    <span class=\"h4\">",
"     Resection, clip placement, tissue advancement, and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the appropriate incision is made, skin flaps are raised along both sides of the wound, dissection is carried down to the chest wall, the breast tissue and pectoralis fascia are lifted off the pectoralis muscle, and a standard cancer resection is performed. After full-thickness excision of the cancer, four to six marking clips are typically placed at the base of the defect within the surrounding fibroglandular tissue to identify the cancer bed for the radiation oncologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The breast tissue is elevated off the chest wall at the plane between the pectoralis muscle and breast gland and advanced to close the defect that results from resection of the cancer. The direction of tissue advancement can be adjusted, depending upon the location of the fibroglandular defect and the excess tissue that can be shifted to close it. The defect is sutured at the deepest edges using interrupted 3-0 absorbable mattress sutures. We typically do not place anchoring stitches into the chest wall, thus allowing the reapproximated breast tissues to move on the chest wall and shift into a natural position when the patient is upright. The subcutaneous tissue is then closed with interrupted absorbable sutures and the skin is closed with absorbable subcuticular sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027095\">",
"    <span class=\"h3\">",
"     Lateral segmentectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral segmentectomy is a variation of the parallelogram-based BCS and is especially useful for cancers located within the lower breast, including the three and nine o&rsquo;clock positions. The skin markings and procedure are illustrated in the figure (",
"    <a class=\"graphic graphic_picture graphicRef62843 \" href=\"UTD.htm?12/10/12454\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin parallelogram is placed radially and, at the corner of the parallelogram that comes closest to the nipple, the design should be positioned such that the closed incision after resection will approach the nipple areolar complex (NAC) tangential to the periareolar line. This reduces deviation of the NAC towards the lesion, a condition that can result from scar contraction. This radial approach gives more projection to the nipple, avoiding the downward-displacement that can be caused by a purely horizontal scar.",
"   </p>",
"   <p>",
"    The remainder of the operation is performed in standard fashion. (See",
"    <a class=\"local\" href=\"#H284599171\">",
"     'Resection, clip placement, tissue advancement, and closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027102\">",
"    <span class=\"h3\">",
"     Batwing mastopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The batwing mastopexy allows resection of cancers adjacent to or deep to the nipple areolar complex (NAC) without sacrifice of the nipple itself. The batwing approach simultaneously preserves NAC viability and the breast mound by using mastopexy closure to close the resulting fibroglandular defect of the full-thickness resection. As this procedure can cause some lifting of the nipple, it may create asymmetry when compared with the contralateral breast. If desired, a contralateral lift can be performed, either concurrently at the time of BCS, or after adjuvant radiation has been completed, and the treated breast has &ldquo;declared&rdquo; its new size and shape. The skin markings and procedure are illustrated in the picture (",
"    <a class=\"graphic graphic_picture graphicRef74595 \" href=\"UTD.htm?35/62/36839\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two semicircular incisions are made with",
"    <strong>",
"    </strong>",
"    angled &ldquo;wings&rdquo; on each side of the areola. The two half-circles are positioned to allow them to be re-approximated to each other at wound closure. Removal of these skin wings allows the semicircles to be shifted together without creating redundant skin folds at closure.",
"   </p>",
"   <p>",
"    The remainder of the operation is performed in standard fashion. (See",
"    <a class=\"local\" href=\"#H284599171\">",
"     'Resection, clip placement, tissue advancement, and closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027109\">",
"    <span class=\"h3\">",
"     Central breast resections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a centrally located cancer and associated NAC involvement do not require mastectomy and are candidates for BCS that includes removal of the NAC and the cancer with negative margins of the fibroglandular tissue. The 10-year actuarial survival, distant disease-free survival, and breast recurrence-free survival for central cancers are not significantly different from patients who present with breast cancer elsewhere in the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Central BCS is particularly valuable in women with large breasts where total mastectomy may create prominent asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H8#H8\">",
"     \"Breast conserving therapy\", section on 'Selection criteria for BCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a central cancer resection, the incision is made in the pattern of a large parallelogram that encompasses the entire NAC. The skin markings and procedure are illustrated in the picture (",
"    <a class=\"graphic graphic_picture graphicRef57697 \" href=\"UTD.htm?20/23/20851\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The remainder of the operation is performed in standard fashion. (See",
"    <a class=\"local\" href=\"#H284599171\">",
"     'Resection, clip placement, tissue advancement, and closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027116\">",
"    <span class=\"h3\">",
"     Reduction mastopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with large breasts (macromastia), a reduction mastopexy can be used for resection of lesions in the lower hemisphere of the breast, between the four and eight o&rsquo;clock positions. Breast reduction can help ensure consistent positioning of the breast for radiotherapy, which improves dosing homogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/20\">",
"     20",
"    </a>",
"    ]. Reduction mastopexy also prevents the down-turning of the nipple that can result from traditional BCS using a circumareolar incision. This procedure is more complicated than most other oncoplastic techniques and should be performed in conjunction with a plastic surgeon. A contralateral reduction should be considered to improve postoperative symmetry. The skin markings and procedure are illustrated in the picture (",
"    <a class=\"graphic graphic_picture graphicRef69551 \" href=\"UTD.htm?9/22/9578\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A keyhole pattern incision is made and the skin above the areola is de-epithelialized in preparation for skin closure. This creates a pedicle on which the NAC can be advanced and preserves the blood supply to the nipple. Depending on the location of the cancer and the size of the breast, it is sometimes preferable to use an inferiorly based pedicle for the NAC. For cancers located in the inferolateral or inferomedial quadrants, the keyhole pattern can be rotated slightly to allow for a more lateral or medial excision, while the NAC is moved in a direction opposite to that of the surgical defect [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/16\">",
"       16",
"      </a>",
"      ]. An inframammary incision is made and breast tissue is dissected off the pectoral fascia to mobilize the NAC and underlying tissues. A full-thickness excision of the lesion with the overlying skin is accomplished, with at least a 1 cm macroscopic margin of normal tissue. Clips should be placed for subsequent radiation planning. (See",
"      <a class=\"local\" href=\"#H284599171\">",
"       'Resection, clip placement, tissue advancement, and closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recentralization of the NAC is performed to recreate a harmonious breast size and shape. The medial and lateral breast flaps are undermined and sutured together to fill the excision defect, leaving a typical inverted-T scar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027123\">",
"    <span class=\"h3\">",
"     Donut mastopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The donut mastopexy technique is best utilized for segmentally distributed cancers located in the upper or lateral breast to achieve resection of long, narrow segments of breast tissue. The donut mastopexy avoids a visible long radial scar, while allowing for adequate margin resection. Only a periareolar scar is visible after this operation. The donut mastopexy lifts the NAC and may create mild asymmetry in comparison to the untreated breast. A contralateral breast lift can be performed to achieve symmetry. The skin markings and procedure are illustrated in the figure (",
"    <a class=\"graphic graphic_picture graphicRef78673 \" href=\"UTD.htm?1/15/1274\">",
"     picture 6",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two concentric incisions are made around the areola and a periareolar &ldquo;donut&rdquo; of skin is excised, taking care to avoid full devascularization of the areolar skin. The width of the &ldquo;donut&rdquo; skin island should be approximately 1 cm, but is somewhat dependant on the size of the areola and expected extent of excision. Removal of this skin is required to allow for both adequate access and exposure to the breast tissue and closure of the skin envelope around the remaining fibroglandular tissue that will reduce tissue volume overall.",
"     </li>",
"     <li>",
"      Skin flaps are raised circumferentially around the nipple-areolar complex.",
"     </li>",
"     <li>",
"      The segment of breast tissue with the cancer is resected in a wedge-shaped fashion, dissected from the underlying pectoralis muscle and delivered through the circumareolar incision.",
"     </li>",
"     <li>",
"      The remaining breast tissue is advanced and the peripheral apical corners of the tissue are secured to each other and then anchored to the chest wall. This anchoring, which is generally not required with smaller oncoplastic resection, maintains proper orientation of the mobilized fibroglandular tissue within the skin envelope during the initial phases of healing and is necessary to prevent the unsightly displacement of the breast that would otherwise result from the large amount of dissection performed. Clips are placed for subsequent radiation planning. (See",
"      <a class=\"local\" href=\"#H284599171\">",
"       'Resection, clip placement, tissue advancement, and closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A purse string suture is placed around the areolar opening at a size that re-approximates the original nipple-areolar complex (NAC) using absorbable suture. Interrupted inverted absorbable sutures are placed subdermally around the NAC, the purse string suture is tied, and absorbable subcuticular sutures are used to close the wound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595442695\">",
"    <span class=\"h2\">",
"     Drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drains are rarely required in most breast-conserving surgery, as any seroma will generally be reabsorbed. However, with more extensive dissections, such as the donut mastopexy, fluid accumulation is more common and may require postoperative aspiration if the patient is symptomatic. There are no randomized trials examining the use of drains in oncoplastic procedures, but, based on our clinical experience, we place suction drains for one to two days in patients with extensive dissections to diminish excessive fluid accumulation in the dissected breast and avoid distortion of the oncoplastic closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595442733\">",
"    <span class=\"h1\">",
"     MARGINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specimen should be removed as a single piece of tissue. Sutures, clips,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multicolored inks are used to orient the specimen by the operating surgeon. Specimen radiography should be performed during the surgical procedure to confirm excision of the targeted lesion. Additional oriented margins can be resected prior to mastopexy closure when the radiograph suggests inadequate resection may have occurred, which may eliminate the need for a delayed re-excision. Intraoperative margin assessment is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H15#H15\">",
"     \"Breast conserving therapy\", section on 'Margins of resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If re-excision is needed for inadequate surgical margins following the initial resection, use of the same incision is preferred. For patients with a positive margin that involves a minority of the specimen, only the involved margin or margins of the previous biopsy cavity need to be excised. The entire biopsy cavity does not need to be re-excised. Indications for re-excision are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H898881#H898881\">",
"     \"Breast conserving therapy\", section on 'Indications for re-excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with multiple positive margins, mastectomy may be necessary. In such cases, it may be technically challenging to include both the initial oncoplastic incision and the nipple areolar complex in the mastectomy. Consultation with a plastic surgeon is recommended if breast reconstruction is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595442643\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat necrosis and delayed healing have been reported with oncoplastic resections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, nipple necrosis may occur if dissection extends high up behind the nipple because the blood supply of the external nipple arises from the underlying breast tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/4\">",
"     4",
"    </a>",
"    ]. Other complications are similar to those after standard breast conserving surgery and are discussed in detail elsewhere. Some of the complications unique to oncoplastic surgery can be prevented by staying in true anatomic planes, meticulous hemostasis, and avoidance of the techniques in patients at higher risk for wound complications (eg, smokers, diabetics, morbidly obese patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H17#H17\">",
"     \"Breast conserving therapy\", section on 'Postoperative Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027151\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term outcomes of oncoplastic surgery are reported as equivalent to standard breast conservation techniques, although prospective studies are not available. As an example, in a study of 540 patients who underwent oncoplastic breast surgery for T2 cancers, the rate of local recurrence was 6.8 percent after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/22\">",
"     22",
"    </a>",
"    ]. The five-year overall and distant disease-free survival rates were 93 and 88 percent respectively. Close or involved margins occurred in 19 percent of patients, and mastectomy was necessary in 9 percent. A lower rate of local recurrence after five years (3 percent) was reported in a study of 146 women who underwent oncoplastic surgery for T2 or T3 cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1512/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14027158\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of breast conserving surgery (BCS) and radiation therapy are to provide the survival equivalent of mastectomy, a cosmetically acceptable breast, and a low rate of recurrence in the treated breast. (See",
"      <a class=\"local\" href=\"#H14027005\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oncoplastic surgical techniques allow resection of a breast cancer with wide surgical margins while preserving the shape and appearance of the breast. (See",
"      <a class=\"local\" href=\"#H101093166\">",
"       'Advantages of oncoplastic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative imaging can help determine whether the lesion can be resected en bloc, whether neoadjuvant chemotherapy is warranted, or if multifocal or multicentric cancer precludes breast conservation or signals potential difficulty in achieving clear surgical margins. Multidisciplinary coordination facilitates treatment planning and streamlines patient care. For complex oncoplastic approaches, plastic surgery consultation or intraoperative collaboration should be arranged. (See",
"      <a class=\"local\" href=\"#H14027026\">",
"       'Patient selection and preoperative considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of oncoplastic surgical technique is based upon the location of the cancer in the breast. (See",
"      <a class=\"local\" href=\"#H370584848\">",
"       'Choice of technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term outcomes of oncoplastic surgery are reported as equivalent to standard breast conservation techniques, although prospective studies are not available. (See",
"      <a class=\"local\" href=\"#H14027151\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/1\">",
"      Silverstein MJ. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 2003; 17:1511.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/3\">",
"      Roughton MC, Shenaq D, Jaskowiak N, et al. Optimizing delivery of breast conservation therapy: a multidisciplinary approach to oncoplastic surgery. Ann Plast Surg 2012; 69:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/4\">",
"      Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. Lancet Oncol 2005; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/5\">",
"      Weiser TG, Haynes AB, Dziekan G, et al. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg 2010; 251:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/6\">",
"      Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: clean non-implant wounds. J Chemother 2001; 13 Spec No 1:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/7\">",
"      Gagliardi AR, Fenech D, Eskicioglu C, et al. Factors influencing antibiotic prophylaxis for surgical site infection prevention in general surgery: a review of the literature. Can J Surg 2009; 52:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/8\">",
"      Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol 2009; 16:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/9\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/10\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/11\">",
"      Braxton CC, Gerstenberger PA, Cox GG. Improving antibiotic stewardship: order set implementation to improve prophylactic antimicrobial prescribing in the outpatient surgical setting. J Ambul Care Manage 2010; 33:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/12\">",
"      Tejirian T, DiFronzo LA, Haigh PI. Antibiotic prophylaxis for preventing wound infection after breast surgery: a systematic review and metaanalysis. J Am Coll Surg 2006; 203:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/13\">",
"      Kronowitz SJ, Feledy JA, Hunt KK, et al. Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg 2006; 117:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/14\">",
"      Nahabedian, MY. Determining the Optimal Approach to Breast Reconstruction after Partial Mastectomy: Discussion. Plast Reconstr Surg 2006; 117:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/15\">",
"      Gainer SM, Lucci A. Oncoplastics: techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol 2011; 103:341.",
"     </a>",
"    </li>",
"    <li>",
"     Grisotti, A. Conservation treatment of breast cancer: Reconstructive problems. In: Surgery of the breast: Principle and art, 2nd edition, Spear, SL (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/17\">",
"      Haffty BG, Wilson LD, Smith R, et al. Subareolar breast cancer: long-term results with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/18\">",
"      Fowble B, Solin LJ, Schultz DJ, Weiss MC. Breast recurrence and survival related to primary tumor location in patients undergoing conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/19\">",
"      Dale PS, Giuliano AE. Nipple-areolar preservation during breast-conserving therapy for subareolar breast carcinomas. Arch Surg 1996; 131:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/20\">",
"      Masetti R, Di Leone A, Franceschini G, et al. Oncoplastic techniques in the conservative surgical treatment of breast cancer: an overview. Breast J 2006; 12:S174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/21\">",
"      Iwuagwu OC. Additional considerations in the application of oncoplastic approaches. Lancet Oncol 2005; 6:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/22\">",
"      Fitoussi AD, Berry MG, Fam&agrave; F, et al. Oncoplastic breast surgery for cancer: analysis of 540 consecutive cases [outcomes article]. Plast Reconstr Surg 2010; 125:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1512/abstract/23\">",
"      Rietjens M, Urban CA, Rey PC, et al. Long-term oncological results of breast conservative treatment with oncoplastic surgery. Breast 2007; 16:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14976 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1512=[""].join("\n");
var outline_f1_30_1512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14027158\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14027005\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101093166\">",
"      ADVANTAGES OF ONCOPLASTIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14027026\">",
"      PATIENT SELECTION AND PREOPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1075282222\">",
"      SURGEON&rsquo;S SAFETY CHECKLIST FOR ONCOPLASTIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14027079\">",
"      ONCOPLASTIC TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H370584485\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H370584848\">",
"      Choice of technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027088\">",
"      - Parallelogram skin incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H284599171\">",
"      Resection, clip placement, tissue advancement, and closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027095\">",
"      - Lateral segmentectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027102\">",
"      - Batwing mastopexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027109\">",
"      - Central breast resections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027116\">",
"      - Reduction mastopexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14027123\">",
"      - Donut mastopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H595442695\">",
"      Drains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H595442733\">",
"      MARGINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H595442643\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14027151\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14027158\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14976|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/0/44040\" title=\"picture 1\">",
"      Parallelogram mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/10/12454\" title=\"picture 2\">",
"      Lateral segmentectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/62/36839\" title=\"picture 3\">",
"      Batwing mastopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/23/20851\" title=\"picture 4\">",
"      Central breast conserving surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/22/9578\" title=\"picture 5\">",
"      Reduction mastopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/15/1274\" title=\"picture 6\">",
"      Donut mastopexy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/28/40395\" title=\"table 1\">",
"      JCAHO protocol for surgical timeout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 2\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35693\" title=\"table 3\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1513="Exercise-induced bronchoconstriction";
var content_f1_30_1513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise-induced bronchoconstriction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Paul M O'Byrne, MB, FRSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1513/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/30/1513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"exercise-induced asthma\" is often used to describe episodic bronchoconstriction following exercise in asthmatic patients. This wording is potentially misleading, since exercise is not an independent risk factor for asthma, but rather a trigger of bronchoconstriction in patients with underlying asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/1\">",
"     1",
"    </a>",
"    ]. In fact, there is some speculation that decreased physical activity is a risk factor for asthma, and that exercise may be helpful in preventing the onset of asthma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the term exercise-induced bronchoconstriction (EIB) is a more accurate reflection of the underlying pathophysiology, and is generally preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of EIB varies from 7 to more than 20 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In comparison, up to 80 percent of patients with symptomatic asthma have some degree of EIB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/6\">",
"     6",
"    </a>",
"    ]. The magnitude of EIB is most strongly correlated with the underlying degree of airway hyperresponsiveness and the presence of airway inflammation, as measured by the number of airway eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Thus, in many patients with mild, episodic asthma, minimally increased airway responsiveness, and mild airway inflammation, even strenuous exercise does not cause clinically significant bronchoconstriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minute ventilation rises with exercise. EIB probably results from changes in airway physiology triggered by the large volume of relatively cool, dry air inhaled during vigorous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This is supported by the finding that EIB is attenuated when the inspired gas is more fully humidified and closer to body temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The effect of large-volume dry air inhalation on airway surface osmolality may be the primary stimulus responsible for bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/13\">",
"     13",
"    </a>",
"    ]. Other relevant observations regarding EIB include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of bronchoconstrictive and inflammatory mediators are increased, particularly leukotrienes LTC4 and LTD4 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/14\">",
"       14",
"      </a>",
"      ], histamine [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/15\">",
"       15",
"      </a>",
"      ], and interleukin (IL)-8 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"       \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral TH2-type lymphocytes are activated, with an increase in T cells expressing CD25 (IL-2R), and B cells expressing CD 23 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/17\">",
"       17",
"      </a>",
"      ]. These changes favor production of IgE and activation of eosinophils. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"       \"Anti-IgE therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophil influx and activation, measured using eosinophilic cationic protein levels, sputum eosinophils, or peripheral eosinophil counts, have been noted in some [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/12,20\">",
"       12,20",
"      </a>",
"      ], studies of experimental EIB.",
"     </li>",
"     <li>",
"      In contrast, exhaled nitric oxide (eNO) levels, which generally reflect airway inflammation, do not appear to correlate well with the development or severity of EIB [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"       \"Exhaled nitric oxide analysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with EIB typically have initial bronchodilation during six to eight minutes of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The initial bronchodilation is followed by",
"    <strong>",
"     bronchoconstriction",
"    </strong>",
"    , which begins by three minutes after exercise, generally peaks within 10 to 15 minutes, and resolves by 60 minutes (",
"    <a class=\"graphic graphic_figure graphicRef64910 \" href=\"UTD.htm?24/22/24941\">",
"     figure 1",
"    </a>",
"    ). Typical symptoms are shortness of breath, chest tightness, and cough. Associated hoarseness or stridor should raise the possibility of paradoxical vocal cord motion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients with EIB, bronchoconstriction is followed by a refractory period, during which repeated exertion causes less bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/26\">",
"     26",
"    </a>",
"    ]. This refractory period is generally less than four hours. Inhibitory prostaglandins (particularly prostaglandin E2) released during the refractory period probably protect against repeated episodes of EIB (",
"    <a class=\"graphic graphic_figure graphicRef78975 \" href=\"UTD.htm?39/34/40493\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute bronchoconstriction was previously believed to be followed by late phase bronchoconstriction in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/28\">",
"     28",
"    </a>",
"    ]. Findings in subsequent studies have been variable [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]; however, it does appear that the risk and severity of late phase bronchoconstriction due to EIB is substantially less than that associated with allergen-induced asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with well documented asthma with typical asthma symptoms following exercise, formal exercise testing is not needed unless symptoms do not resolve with, or are not prevented by, pretreatment with inhaled beta agonists. In patients without documented asthma, further assessment is helpful to ensure that alternative causes of dyspnea are not overlooked and that unnecessary therapy is not prescribed. This is particularly true when an adult develops new onset exercise related symptoms. Formal testing is also helpful in evaluating highly trained athletes, as exercise related respiratory symptoms are poor predictors of EIB in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exercise challenge test is the most direct way to establish a diagnosis of EIB. This usually involves six to eight minutes of ergometer or treadmill exercise, sufficient to raise the heart rate to 85 percent of the predicted maximum. A test is generally considered positive if the FEV1 falls by 10 percent or more, although a fall of 15 percent is more diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/25,33\">",
"     25,33",
"    </a>",
"    ]. Alternatively, surrogate tests to assess bronchial hyperresponsiveness (eg, cold air hyperventilation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , histamine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    inhalation challenge) may be performed in specialized laboratories, but do not always correlate with the presence of EIB [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of peak expiratory flow rates before and after exercise frequently leads to inaccurate results, but portable devices that record forced expiratory volume in one second (FEV1) are more accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/33\">",
"     33",
"    </a>",
"    ]. After a baseline value has been established, FEV1 can be measured before and 2.5, 5, 10, 15, and 30 minutes after exercise and correlated with symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of exercise-induced dyspnea must be considered, particularly in patients who have no other manifestations of asthma and derive no benefit from pretreatment with bronchodilators. Central airway obstruction, vocal cord dysfunction, laryngotracheomalacia, parenchymal pulmonary disease, gastroesophageal reflux, coronary heart disease, and heart failure should also be considered in adults who present with atypical exercise-induced dyspnea.",
"   </p>",
"   <p>",
"    The differential diagnosis is similar among children. In one retrospective review, treadmill exercise testing was performed in 142 children referred to a pediatric allergy and pulmonology clinic with exercise-induced dyspnea who had no other signs of asthma or in whom treatment with beta-2-agonists had failed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/39\">",
"     39",
"    </a>",
"    ]. Symptoms of exercise-induced dyspnea were reproduced in 82 percent. Among these 117 children, only 11 (9 percent) had EIB (defined by reproduction of symptoms and &ge;15 percent decrease in FEV1 from baseline). Other diagnoses included normal physiologic exercise limitation (63 percent), restrictive abnormalities (13 percent), vocal cord dysfunction (11 percent); laryngomalacia (2 percent), and hyperventilation and supraventricular tachycardia, each in one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of general measures and pharmacologic intervention can prevent EIB in almost all asthmatics. A major goal is to",
"    <strong>",
"     ensure that exercise is not avoided",
"    </strong>",
"    by patients with EIB. Asthmatics should exercise as much as desired, and should be encouraged by the fact that athletes have won Olympic medals and played professional sports, in spite of symptomatic asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved understanding of the pathophysiology of EIB has resulted in general recommendations that can help reduce its severity. These measures are based upon observed relationships between the severity of bronchoconstriction and the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The magnitude of minute ventilation",
"     </li>",
"     <li>",
"      The temperature and humidity of the inspired air",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improving a patient's cardiovascular fitness reduces the minute ventilation required for a given level of exercise, thereby decreasing the stimulus for bronchoconstriction. Similarly, bronchoconstriction is lessened when the inspired gas is warmer and more humid. Patients should be instructed to breathe through a loosely fitting scarf or mask when exercising in cold, dry conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Finally, ensuring that patients know when and how to use a metered dose or dry powder inhaler correctly can greatly enhance the efficacy of pharmacologic measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to therapy can be assessed subjectively in terms of symptom control and exercise tolerance. Peak expiratory flow measurement before and after exercise may be helpful. If objective measurement of a patient's response to therapy is required, a formal exercise test, rather than the more widely available",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge, should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of EIB has been studied primarily in patients with both EIB",
"    <strong>",
"     and",
"    </strong>",
"    underlying asthma. Therapeutic options for patients with EIB as the",
"    <strong>",
"     only",
"    </strong>",
"    manifestation of airway hyperresponsiveness are less well researched. In general, if EIB occurs frequently in patients with poorly controlled asthma, the most important strategy is to improve overall asthma control [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/44\">",
"     44",
"    </a>",
"    ]. Inhaled glucocorticoids and leukotriene-modifying agents are often useful in this regard. Prophylactic treatment of EIB prior to exercise, using inhaled beta-2 agonists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    , should be considered in all patients with EIB, even if EIB is the sole manifestation of airway hyperresponsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Beta-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with significant EIB should be instructed to use prophylactic treatment approximately 10 minutes before exercise, usually with two puffs of a rapid-acting inhaled beta-2 agonist (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Patients with more severe asthma may require higher prophylactic doses of inhaled beta-2 agonists. Equipotent doses of formoterol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    appear to be equally effective in providing short-term control of EIB, although the onset of action is slower with salmeterol than with the other agents (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children often present a difficult clinical situation by exercising vigorously and intermittently throughout the day without pretreating themselves prior to exercise. In this setting, long-acting inhaled beta-2 agonists (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) provide protection against EIB for most of the day [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, both long-acting inhaled beta-2 agonists and regular use of short-acting inhaled beta-2 agonists provide less effective protection against EIB than does intermittent prophylactic use of beta-2 agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend regular use of long-acting beta agonists (ie, once or twice daily) as monotherapy for EIB, because of concerns about a loss of bronchoprotective effect over time [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, for patients who require regular dosing of a long-acting beta-agonist (LABA) to control EIB, we recommend concomitant use of inhaled glucocorticoid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    , or an anti-leukotriene agent. Patients who require a preventive short-acting beta-agonist (SABA) once every day may also want to consider using one of these alternate agents.",
"   </p>",
"   <p>",
"    The World Anti-Doping Agency has listed beta-agonists on its prohibited medication list [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Competitive athletes may need to file Therapeutic Use Exceptions for use of inhaled beta-agonists during elite competition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cromoglycates",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach is prophylactic use of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    (two to four puffs from a metered dose inhaler) taken 15 to 20 minutes before exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/56\">",
"     56",
"    </a>",
"    ]. In exceptional situations, as with very high performance athletes or patients exercising in extreme conditions (eg, very cold, dry air), the combination of four puffs of an inhaled beta-2 agonist and four puffs of cromoglycate is likely to be more effective than either drug used alone, as demonstrated in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/57\">",
"     57",
"    </a>",
"    ]. The effect of cromolyn given in 2 mg or 10 mg doses is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     Nedocromil",
"    </a>",
"    sodium is as effective as cromolyn sodium in protecting against EIB, but offers no clear advantage (",
"    <a class=\"graphic graphic_table graphicRef56418 \" href=\"UTD.htm?32/17/33052\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/56,59,60\">",
"     56,59,60",
"    </a>",
"    ]. Neither is effective for relief of bronchoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;When poor asthma control is the cause of refractory exercise-induced bronchoconstriction, the most effective method of achieving asthma control involves use of inhaled glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef58247 graphicRef71181 graphicRef80908 \" href=\"UTD.htm?36/19/37183\">",
"     table 3A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although inhaled glucocorticoids will not improve EIB in the short term, they do improve airway hyperresponsiveness and, over weeks to months, decrease the magnitude of bronchoconstriction that occurs with a given workload [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have noted that inhaled glucocorticoids do not decrease EIB in a dose-related manner [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In contrast, a decrease in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    sensitivity (as determined by methacholine challenge) is generally well-correlated with the inhaled glucocorticoid dose. These findings suggest both a mechanism for EIB distinct from methacholine, and considerable variability in response to inhaled glucocorticoid therapy. This variability is partially explained by a greater magnitude of benefit from inhaled glucocorticoids in patients with higher sputum eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Anti-Doping Agency has listed inhaled glucocorticoids on its prohibited medication list [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/55\">",
"     55",
"    </a>",
"    ]. Competitive athletes may need to file Therapeutic Use Exceptions for use of inhaled glucocorticoids during elite competition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antileukotriene agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene modifying agents provide an attractive therapeutic alternative in the setting of chronic asthma complicated by EIB (",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"     table 4",
"    </a>",
"    ). Urinary leukotrienes increase after exercise in patients with EIB, and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    attenuates this response, in addition to improving clinical control [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/14,65\">",
"     14,65",
"    </a>",
"    ]. Protection from EIB is apparent by two hours after a single dose of montelukast, and post-exercise recovery is accelerated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The long half-life of this agent allows once-daily dosing with durable protection from EIB for up to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. However, leukotriene receptor antagonists are not effective in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leukotriene-modifying agents appear superior to inhaled long-acting beta-2 agonists when treating asthmatics with EIB. In one blinded multicenter trial, asthmatics with EIB were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/70\">",
"     70",
"    </a>",
"    ]. Therapy was protective within three days for both groups; however, tolerance to salmeterol developed, and by eight weeks, the bronchoprotective effect of montelukast was significantly better (",
"    <a class=\"graphic graphic_figure graphicRef69196 \" href=\"UTD.htm?2/58/2991\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As mentioned above, children with EIB can pose a therapeutic challenge, because they tend to exercise intermittently throughout the day and often neglect to premedicate with an inhaled beta agonist. Antileukotrienes are an effective option in this setting.",
"   </p>",
"   <p>",
"    In a randomized, double blind study of EIB in children,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    and montelukast with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    were superior to budesonide and budesonide with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diets rich in anti-inflammatory omega-3 fatty acids have not been conclusively demonstrated to be helpful in the general population of patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/71\">",
"     71",
"    </a>",
"    ]. However, in the subset of patients with EIB, there have been more promising results. In a randomized, double blind, crossover study of 16 patients treated for three weeks with either fish oil supplements (containing omega-3 fatty acids) or placebo, the group on fish oil had reduced leukotriene, PGD2, IL-1 beta, and TNF alpha in induced sputa. Pulmonary function improved and bronchodilator use was reduced. This suggests that, in asthmatics with EIB, a diet enriched with omega-3 fatty acids may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other types of asthma therapy are",
"    <strong>",
"     not",
"    </strong>",
"    very effective in protecting against EIB. As an example, oral beta-2 agonists and methylxanthines are marginally effective or ineffective in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other drugs have been tested as possible prophylactic agents against EIB. Inhaled medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/75\">",
"     75",
"    </a>",
"    ], prostaglandin E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/76\">",
"     76",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/77\">",
"     77",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1513/abstract/78\">",
"     78",
"    </a>",
"    ], may protect against EIB. However, long-term clinical use of these compounds has not been directly compared with the prophylactic use of inhaled beta-2 agonists. For this reason, their role in clinical practice is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breakthrough symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients forget to take prophylactic therapy for EIB or if they experience breakthrough symptoms despite treatment, bronchoconstriction should be treated with two to four puffs of an inhaled beta-2 agonist.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    effective in this situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=see_link\">",
"       \"Patient information: Exercise-induced asthma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-induced bronchoconstriction (EIB) refers to the episodic bronchoconstriction that follows exercise in many asthmatic patients. This reflects the view that exercise is a trigger of bronchoconstriction in patients with underlying asthma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improving a patient's cardiovascular fitness reduces the minute ventilation required for a given level of exercise, thereby decreasing the stimulus for bronchoconstriction. Avoiding exercise in cold, dry air can also reduce the stimulus for exercise-induced bronchoconstriction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of EIB varies somewhat with the clinical setting. The first priority in patients with uncontrolled asthma is to step up treatment to achieve control of asthma. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with asthma should have a rapid-acting beta agonist available when exercising for relief of asthma symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have well-controlled asthma, but who frequently have asthma symptoms with exercise, we recommend prophylactic use of a rapid-acting beta agonist approximately 10 minutes prior to exercise (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Alternatively, in patients who develop side effects from a beta-agonist, a cromoglycate can be used 15 to 20 minutes prior to exercise. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Beta-agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When neither a prophylactic beta-agonist nor a cromoglycate is adequate to prevent exercise-induced bronchoconstriction, we suggest adding an inhaled glucocorticoid or a leukotriene agent rather than using a long-acting beta agonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In this setting, poor control of underlying asthma may be contributing to the exercise related respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Beta-agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For particularly strenuous exercise or exercise in extreme conditions, a combination of inhaled beta agonist and a cromoglycate may be helpful. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cromoglycates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who require daily therapy for EIB, we suggest regular use of an anti-leukotriene agent or an inhaled glucocorticoid rather than regular daily use of a beta agonist alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When exercise is unpredictable or repeated during the day (eg, in children), we suggest a daily morning dose of a leukotriene receptor antagonist rather than a pre-exercise inhaler (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antileukotriene agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and oral beta agonists are minimally effective or ineffective for EIB. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/1\">",
"      Storms WW. Asthma associated with exercise. Immunol Allergy Clin North Am 2005; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/2\">",
"      Lucas SR, Platts-Mills TA. Physical activity and exercise in asthma: relevance to etiology and treatment. J Allergy Clin Immunol 2005; 115:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/3\">",
"      Sonna LA, Angel KC, Sharp MA, et al. The prevalence of exercise-induced bronchospasm among US Army recruits and its effects on physical performance. Chest 2001; 119:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/4\">",
"      Ng'ang'a LW, Odhiambo JA, Mungai MW, et al. Prevalence of exercise induced bronchospasm in Kenyan school children: an urban-rural comparison. Thorax 1998; 53:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/5\">",
"      Kukafka DS, Lang DM, Porter S, et al. Exercise-induced bronchospasm in high school athletes via a free running test: incidence and epidemiology. Chest 1998; 114:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/6\">",
"      McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/7\">",
"      Anderton RC, Cuff MT, Frith PA, et al. Bronchial responsiveness to inhaled histamine and exercise. J Allergy Clin Immunol 1979; 63:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/8\">",
"      Duong M, Subbarao P, Adelroth E, et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest 2008; 133:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/9\">",
"      McFadden ER Jr, Ingram RH Jr. Exercise-induced asthma: Observations on the initiating stimulus. N Engl J Med 1979; 301:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/10\">",
"      Anderson SD, Schoeffel RE, Black JL, Daviskas E. Airway cooling as the stimulus to exercise-induced asthma--a re-evaluation. Eur J Respir Dis 1985; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/11\">",
"      Deal EC Jr, McFadden ER Jr, Ingram RH Jr, et al. Role of respiratory heat exchange in production of exercise-induced asthma. J Appl Physiol 1979; 46:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/12\">",
"      Kallings LV, Emtner M, B&auml;cklund L. Exercise-induced bronchoconstriction in adults with asthma--comparison between running and cycling and between cycling at different air conditions. Ups J Med Sci 1999; 104:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/13\">",
"      Freed AN, Davis MS. Hyperventilation with dry air increases airway surface fluid osmolality in canine peripheral airways. Am J Respir Crit Care Med 1999; 159:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/14\">",
"      Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/15\">",
"      Hartley JP, Nogrady SG. Effect of an inhaled antihistamine on exercise-induced asthma. Thorax 1980; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/16\">",
"      Hashimoto S, Gon Y, Matsumoto K, et al. Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells. Am J Respir Crit Care Med 2000; 162:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/17\">",
"      Hallstrand TS, Ault KA, Bates PW, et al. Peripheral blood manifestations of T(H)2 lymphocyte activation in stable atopic asthma and during exercise-induced bronchospasm. Ann Allergy Asthma Immunol 1998; 80:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/18\">",
"      Kivity S, Argaman A, Onn A, et al. Eosinophil influx into the airways in patients with exercise-induced asthma. Respir Med 2000; 94:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/19\">",
"      Yoshikawa T, Shoji S, Fujii T, et al. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflammation in patients with asthma. Eur Respir J 1998; 12:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/20\">",
"      Gauvreau GM, Ronnen GM, Watson RM, O'Byrne PM. Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma. Am J Respir Crit Care Med 2000; 162:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/21\">",
"      De Gouw HW, Marshall-Partridge SJ, Van Der Veen H, et al. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. J Appl Physiol 2001; 90:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/22\">",
"      Scollo M, Zanconato S, Ongaro R, et al. Exhaled nitric oxide and exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 2000; 161:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/23\">",
"      Shin HW, Schwindt CD, Aledia AS, et al. Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/24\">",
"      Inman MD, Watson RM, Killian KJ, O'Byrne PM. Methacholine airway responsiveness decreases during exercise in asthmatic subjects. Am Rev Respir Dis 1990; 141:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/25\">",
"      Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/26\">",
"      Edmunds AT, Tooley M, Godfrey S. The refractory period after exercise-induced asthma: its duration and relation to the severity of exercise. Am Rev Respir Dis 1978; 117:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/27\">",
"      Manning PJ, Watson RM, O'Byrne PM. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin interdependent mechanisms. Am Rev Respir Dis 1993; 148:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/28\">",
"      Iikura Y, Inui H, Nagakura T, Lee TH. Factors predisposing to exercise-induced late asthmatic responses. J Allergy Clin Immunol 1985; 75:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/29\">",
"      Rubinstein I, Levison H, Slutsky AS, et al. Immediate and delayed bronchoconstriction after exercise in patients with asthma. N Engl J Med 1987; 317:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/30\">",
"      Chhabra SK, Ojha UC. Late asthmatic response in exercise-induced asthma. Ann Allergy Asthma Immunol 1998; 80:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/31\">",
"      Koh YY, Jeong JH, Jin SM, et al. The occurrence of late asthmatic response to exercise after allergen challenge. Ann Allergy Asthma Immunol 1998; 81:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/32\">",
"      Tateishi K, Motojima S, Kushima A, et al. Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. Ann Allergy Asthma Immunol 1996; 77:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/33\">",
"      Weiler JM, Bonini S, Coifman R, et al. American Academy of Allergy, Asthma &amp; Immunology Work Group report: exercise-induced asthma. J Allergy Clin Immunol 2007; 119:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/34\">",
"      Bonini S, Brusasco V, Carlsen KH, et al. Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy 2004; 59:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/35\">",
"      Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J Allergy Clin Immunol 2003; 111:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/36\">",
"      Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006; 117:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/37\">",
"      Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest 2004; 125:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/38\">",
"      Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Am J Respir Crit Care Med 1998; 158:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/39\">",
"      Abu-Hasan M, Tannous B, Weinberger M. Exercise-induced dyspnea in children and adolescents: if not asthma then what? Ann Allergy Asthma Immunol 2005; 94:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/40\">",
"      Millqvist E, Bake B, Bengtsson U, L&ouml;whagen O. A breathing filter exchanging heat and moisture prevents asthma induced by cold air. Allergy 1995; 50:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/41\">",
"      Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. Chest 2006; 129:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/42\">",
"      Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/43\">",
"      Freezer NJ, Croasdell H, Doull IJ, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995; 8:1488.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/45\">",
"      Anderson S, Seale JP, Ferris L, et al. An evaluation of pharmacotherapy for exercise-induced asthma. J Allergy Clin Immunol 1979; 64:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/46\">",
"      Richter K, Janicki S, J&ouml;rres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002; 19:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/47\">",
"      Newnham DM, Ingram CG, Earnshaw J, et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med 1993; 87:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/48\">",
"      Vilsvik J, Ankerst J, Palmqvist M, et al. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. Respir Med 2001; 95:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/49\">",
"      Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002; 165:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/50\">",
"      Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/51\">",
"      Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/52\">",
"      Garc&iacute;a R, Guerra P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Investig Allergol Clin Immunol 2001; 11:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/53\">",
"      Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/54\">",
"      Carlsen KH, Anderson SD, Bjermer L, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN. Allergy 2008; 63:492.",
"     </a>",
"    </li>",
"    <li>",
"     World Anti-Doping Agency www.wada-ama.org (Accessed on June 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/56\">",
"      de Benedictis FM, Tuteri G, Bertotto A, et al. Comparison of the protective effects of cromolyn sodium and nedocromil sodium in the treatment of exercise-induced asthma in children. J Allergy Clin Immunol 1994; 94:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/57\">",
"      Latimer KM, O'Byrne PM, Morris MM, et al. Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone. Am Rev Respir Dis 1983; 128:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/58\">",
"      Storm van's Gravesande K, Mattes J, Grossklauss E, et al. Preventive effect of 2 and 10 mg of sodium cromoglycate on exercise-induced bronchoconstriction. Eur J Pediatr 2000; 159:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/59\">",
"      Spooner C, Rowe BH, Saunders LD. Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis. Eur Respir J 2000; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/60\">",
"      Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2002; :CD001183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/61\">",
"      J&oacute;nasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. Pediatr Allergy Immunol 2000; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/62\">",
"      J&oacute;nasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/63\">",
"      Stelmach I, Grzelewski T, Majak P, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/64\">",
"      Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev 2007; :CD002739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/65\">",
"      Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/66\">",
"      Philip G, Villar&aacute;n C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/67\">",
"      Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/68\">",
"      Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/69\">",
"      Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002; 32:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/70\">",
"      Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/71\">",
"      Reisman J, Schachter HM, Dales RE, et al. Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. BMC Complement Altern Med 2006; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/72\">",
"      Mickleborough TD, Lindley MR, Ionescu AA, Fly AD. Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 2006; 129:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/73\">",
"      Ellis EF. Inhibition of exercise-induced asthma by theophylline. J Allergy Clin Immunol 1984; 73:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/74\">",
"      Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study. Eur Respir J 1993; 6:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/75\">",
"      Bianco S, Vaghi A, Robuschi M, Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988; 2:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/76\">",
"      Melillo E, Woolley KL, Manning PJ, et al. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994; 149:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/77\">",
"      Shimizu T, Mochizuki H, Shigeta M, Morikawa A. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med 1997; 155:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1513/abstract/78\">",
"      Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 1999; 160:576.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 533 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1513=[""].join("\n");
var outline_f1_30_1513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Beta-agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cromoglycates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antileukotriene agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breakthrough symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/533|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/22/24941\" title=\"figure 1\">",
"      Time course bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/34/40493\" title=\"figure 2\">",
"      Repeated exercise challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/58/2991\" title=\"figure 3\">",
"      Montelukast and exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/533|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15917\" title=\"table 1\">",
"      Doses beta agonist preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/17/33052\" title=\"table 2\">",
"      Dosing of cromolyn sodium and nedocromil in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 3A\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/62/27629\" title=\"table 3B\">",
"      Initiating Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/40/9869\" title=\"table 3C\">",
"      Initiating Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/12/20683\" title=\"table 4\">",
"      Usual doses antileukotriene",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/26/1442?source=related_link\">",
"      Patient information: Exercise-induced asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1514="Azithromycin, clarithromycin, and telithromycin";
var content_f1_30_1514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Azithromycin, clarithromycin, and telithromycin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1514/contributors\">",
"     Amy L Graziani, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1514/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/30/1514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/30/1514/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/30/1514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (Zithromax) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (Biaxin) are macrolide antibiotics that are used in the treatment of community-acquired respiratory tract infections, particularly pneumonia. They are derivatives of the older macrolide antibiotic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . Structural modifications of erythromycin cause a change in the spectrum of activity, dosing, and administration of the newer macrolides and ketolides.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    (Ketek) is the first member of the ketolide class of antimicrobials, which is related to the macrolide class. Concerns about postmarketing reports of hepatotoxicity and exacerbations of myasthenia gravis have led to significant restrictions on the use of telithromycin. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Warnings about telithromycin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The spectrum of activity, mechanisms of action and resistance, pharmacokinetics, interactions with other drugs, and adverse effects of these newer macrolide antibiotics will be reviewed here. The use of these drugs for community-acquired pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The macrolides are sometimes used for their antiinflammatory effects. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link&amp;anchor=H14#H14\">",
"     \"Diffuse panbronchiolitis\", section on 'Macrolide antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION AND CHEMICAL STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of the newer macrolides is similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . They bind to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation, translocation, chain elongation and, ultimately, bacterial protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    has the same macrolide, 14-membered lactone ring as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ; the only difference is that at position six a methoxy group replaces the hydroxyl group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    , in comparison, has a 15-membered ring and a methyl-substituted nitrogen replacing the 9A carbonyl group. For this reason, azithromycin is more precisely referred to as an azalide rather than a macrolide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These structural changes have made the newer macrolides more acid-stable than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , providing improved oral absorption, tolerance, and pharmacokinetic properties. The newer macrolides also have a broader spectrum of antibacterial activity than erythromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ketolide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    , was designed to specifically target macrolide-resistant respiratory tract pathogens. It has a keto group substituted for the L-cladinose at C3, a methoxy group at C6, and an N-substituted carbamate at",
"    <span class=\"nowrap\">",
"     C11/C12.",
"    </span>",
"    These modifications enable telithromycin to bind more tightly to ribosomal RNA, which increases its potency, decreases the selection of bacterial resistance, increases its activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -resistant strains, and improves the pharmacokinetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired macrolide resistance is an increasing problem. As with resistance to other drugs, antibiotic use has been associated with development of resistance. This relationship was directly demonstrated in a randomized, double-blind trial in which 224 healthy volunteers were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , or placebo; the end point was the development of pharyngeal carriage of macrolide-resistant streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/5\">",
"     5",
"    </a>",
"    ]. The proportion of macrolide-resistant streptococci was 26 to 30 percent at baseline. Both macrolides significantly increased the proportion of macrolide-resistant streptococci compared to placebo, peaking at day four to eight, with a mean increase of about 50 percent (to an absolute proportion of over 80 percent) compared with a 4 percent increase with placebo. The increase in resistance was greater with azithromycin, a possible reflection of its much longer half-life.",
"   </p>",
"   <p>",
"    Two main mechanisms of acquired macrolide resistance have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Methylases encoded by the erm (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ribosome methylase) genes (ermA, ermB, ermC) alter the macrolide binding site on the bacterial ribosomal RNA, usually conferring a high degree of macrolide resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/9\">",
"       9",
"      </a>",
"      ]. In a study of selected resistance in volunteers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      selected for this type of resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/5\">",
"       5",
"      </a>",
"      ]. This mechanism also usually confers resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23159?source=see_link&amp;anchor=H3#H3\">",
"       \"Clindamycin: An overview\", section on 'Resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Active macrolide efflux pumps, encoded by the mef (macrolide efflux) msrA and msrB genes, confer a low to moderate degree of macrolide resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These mechanisms are responsible for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    resistance in most gram-positive cocci (eg, Staphylococcus aureus, Streptococcus pneumoniae, other streptococci). In contrast to the mechanisms of acquired resistance, intrinsic resistance exhibited by Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp is due to decreased permeability of the outer cell envelope.",
"   </p>",
"   <p>",
"    Mechanisms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    are the same as or similar to those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . There is complete cross-resistance between erythromycin, azithromycin, and clarithromycin for gram-positive organisms by the alteration in ribosomal RNA mechanism. In contrast, resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    by this mechanism is as yet uncommon; as a result, telithromycin is active against many erythromycin-resistant respiratory pathogens. However, resistance due to ketolide efflux pumps can cause resistance to telithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/12\">",
"     12",
"    </a>",
"    ]. Telithromycin-resistant isolates have been isolated in vitro, and a case report has documented a telithromycin-resistant S. pneumoniae isolate recovered from blood following telithromycin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of macrolide-resistant S. pneumoniae isolates increased from 10.6 percent in 1995 to 20.4 percent in 1999. However, in cities in the United States where pneumococcal vaccination of children has been widespread, there was a distinct reduction in the overall prevalence of macrolide resistance among invasive isolates in 2002. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link&amp;anchor=H4#H4\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\", section on 'Prevalence of resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    have enhanced gram-negative activity compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . As a result, selected erythromycin-resistant gram-negative organisms may be sensitive to the newer drugs.",
"   </p>",
"   <p>",
"    Increasing resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    has been described in patients with syphilis; the frequency varies with geographic area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H40#H40\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    have a broader spectrum of activity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest use of the macrolides is in upper respiratory tract infections;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    have activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -sensitive Streptococcus pneumoniae, Haemophilus spp, Moraxella catarrhalis, and atypical pneumonia pathogens, including Legionella pneumophila, Chlamydophila (formerly Chlamydia) pneumoniae, and Mycoplasma pneumoniae. Telithromycin also has activity against many erythromycin-resistant S. pneumoniae. Azithromycin is more effective in vitro against most strains of H. influenzae, and has more rapid killing and a longer post-antibiotic effect than clarithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Despite the fact that clarithromycin&rsquo;s 14-hydroxy metabolite has activity against H. influenzae, in one study, only 63 percent of H. influenzae isolates were susceptible to clarithromycin, whereas 96 percent were susceptible to azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/16\">",
"     16",
"    </a>",
"    ]. For this reason, azithromycin is preferred over clarithromycin in outpatients with community-acquired pneumonia who have comorbidities, such as chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/15\">",
"     15",
"    </a>",
"    ]. Erythromycin does not have activity against H. influenzae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H20#H20\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Macrolide resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These antibiotics are also usually active against other gram-positive organisms including Staphylococcus aureus (except for methicillin-resistant S. aureus), and Group A, B, C, and G streptococcus.",
"   </p>",
"   <p>",
"    Resistance to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    by gram-positive organisms results in cross resistance to the other macrolides; however, this cross resistance is not necessarily true with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    . As an example, telithromycin is active against many",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -resistant S. pneumoniae and Streptococcus pyogenes and is more active than azithromycin and clarithromycin in vitro against erythromycin-sensitive S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The newer macrolides have enhanced gram-negative activity compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . As a result, an erythromycin-resistant gram-negative organism may be sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    . The gram-negative spectrum includes activity against Escherichia coli, Salmonella spp, Yersinia enterocolitica, Shigella spp, Campylobacter jejuni, Vibrio cholerae, Neisseria gonorrhoeae, and Helicobacter pylori.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are the primary agents used to treat Mycobacterium avium complex infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     METABOLISM AND PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    have improved oral absorption, longer serum half-lives, and better tissue and intracellular penetration than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . Only azithromycin is available in an intravenous formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acid stability and food",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    are stable at gastric pH. As a result, their bioavailability is better than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    base (37 versus 25 percent), and enteric coating is not required. All of the newer tablet formulations and oral suspensions, except for extended-release clarithromycin, can be taken with or without food [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,4,17\">",
"     1,4,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum concentrations attained with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are much lower than those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A regimen of 500 mg on day one followed by 250",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for nine days leads to an average plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      concentration of 0.21",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/2-4,18,19\">",
"       2-4,18,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The extended-release oral suspension of azithromycin (Zmax, given as a single dose per week) results in a higher peak serum concentration and more systemic exposure than can be achieved with standard regimens of immediate-release azithromycin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The oral bioavailability of the original",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (dosed every 12 hours) tablets is approximately 50 percent; the mean steady state peak serum concentration following 500 mg orally every 12 hours is 2 to 3",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The newer, extended-release clarithromycin tablets (Biaxin XL, dosed once daily) have inactive ingredients in the tablet that bind to clarithromycin and slow gastric absorption. The peak serum concentration is lower than the original clarithromycin tablets and is delayed until five to eight hours following the dose. Patients should be instructed to take the extended-release tablets with food because fasting decreases the area under the plasma concentration-time curve (AUC) by 30 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is well absorbed from the GI tract (90 percent), but a third of the dose is metabolized via first pass metabolism by the liver and intestine, resulting in an oral bioavailability of 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/12\">",
"     12",
"    </a>",
"    ]. Peak plasma levels one to two hours after an 800 mg oral dose are 1.8 to 2.2",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    The plasma half-life is 9.8 hours at steady state [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/22\">",
"     22",
"    </a>",
"    ]. Food does not affect the rate or extent of absorption of telithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tissue and intracellular penetration",
"    </span>",
"    &nbsp;&mdash;&nbsp;All macrolides and ketolides distribute and concentrate well in most body tissues and phagocytic cells. Thus, the tissue levels, epithelial lining fluid, and alveolar macrophage concentrations are usually higher than those in the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is the most highly concentrated in tissue, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Telithromycin achieves concentrations in lower respiratory tract infection sites that are higher than the MICs of most respiratory pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, telithromycin concentrates intracellularly in alveolar macrophages (at least 400-fold higher than concomitant serum concentrations) and in polymorphonuclear cells (200 to 300-fold higher than concomitant serum concentrations) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/14,23\">",
"     14,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    levels in sputum and lung are 10 to 100 times those in the plasma; alveolar macrophage and neutrophil concentrations are also higher [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/2,4,21\">",
"     2,4,21",
"    </a>",
"    ]. In comparison,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    levels in the lung are only six to eight times higher than the plasma concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences in intracellular penetration and plasma concentration are two reasons that comparison of these agents by traditional, in vitro methods (such as MIC) is difficult. The clinical significance of the better tissue penetration but lower plasma levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Active metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is excreted in the bile and then the feces, with very little unchanged drug appearing in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Several azithromycin metabolites have been identified, but none is known to be biologically active [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/4,24\">",
"     4,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is hydroxylated, N-demethylated, and hydrolyzed in the liver, utilizing the cytochrome P450 enzyme system. The major metabolite, 14-hydroxy-clarithromycin, is microbiologically active [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and it is more active than the parent compound against some species. As an example, among H. influenzae isolates from patients with community-acquired pneumonia, the concentration at which 90 percent of organisms are inhibited (MIC90) of the 14-OH metabolite was 3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    compared with 9",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for the parent compound [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/16\">",
"     16",
"    </a>",
"    ]. This active clarithromycin metabolite is another variable that makes a comparison between clarithromycin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    difficult in vitro. Twenty to 30 percent of clarithromycin is excreted unchanged in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    has multiple routes of elimination: seven percent is eliminated in the feces, 13 percent is excreted unchanged in the urine, and the remainder is metabolized by hepatic CYP450 and non-CYP450 pathways. Up to four major metabolites appear to have antibacterial activity, although the activity is weak, only about 6 percent as potent as telithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is typically given for a shorter period because of the long intracellular half-life (40 to 68 hours) and slow release from tissue sites. Thus, for many infections, a once-daily, five day regimen is as effective as 10 day courses of the other macrolides.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is available in several different formulations, including 250, 500, and 600 mg tablets and a 100",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL or 200",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL pediatric preparation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is also available as an intravenous formulation. The infusion volumes are relatively large (250 mL to 500 mL) and the infusion rates are long (three hours for the 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    concentration and one hour for the 2",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    concentration).",
"   </p>",
"   <p>",
"    The 2 g extended-release oral suspension of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (Zmax) has an even shorter regimen as it is given as a single dose, because of the long half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clarithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is available in the original tablets (250 and 500 mg) and extended release tablets (Biaxin XL, 500 mg). There is no intravenous formulation.",
"   </p>",
"   <p>",
"    A pediatric formulation is available including tablets or granules for oral suspension (125",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL and 250",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/24\">",
"     24",
"    </a>",
"    ]. The suspension should not be refrigerated because it can become very viscous and difficult to shake adequately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Warnings about telithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is available in 400 mg tablets. There is no intravenous formulation.",
"   </p>",
"   <p>",
"    Because of reports of potentially fatal hepatotoxicity, potentially fatal exacerbations of myasthenia gravis, and visual disturbances, the United States Food and Drug Administration (FDA) concluded in February 2007 that the risks associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    outweigh its benefits for minor illnesses, and that telithromycin should",
"    <strong>",
"     not",
"    </strong>",
"    be used to treat sinusitis or bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/26\">",
"     26",
"    </a>",
"    ]. Even among patients with mild to moderate community-acquired pneumonia, the FDA concluded that telithromycin should be a secondary alternative to other antimicrobial drugs. A black box warning was added to the label stating that telithromycin should not be used in patients with myasthenia gravis. There has been some controversy over the review and monitoring of the hepatotoxicity pre- and postmarketing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    dosing does not require adjustment with decreased creatinine clearance. In patients with a creatinine clearance below 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    should be reduced by half or the dosing interval should be doubled.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    dosing does not require adjustment with mild-to-moderate renal impairment (creatinine clearance &ge;30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    No dose has been established for patients with severe renal impairment, but the drug accumulates with decreased renal function. As a result, dose adjustment should be considered in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    should be considered the safest macrolide in pregnant women, because of the many years of clinical experience. Of the newer macrolides, there is more experience during pregnancy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is a United States Food and Drug Administration (FDA) pregnancy category B drug (ie, no evidence of risk in pregnant humans), the same category as for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several reports of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In two studies, patients with cervical chlamydial infection received a 1 g dose of azithromycin and were followed for efficacy and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Teratogenic effects were not noted, although it is not clear if neonatal examination and follow-up were required. More recently, 123 pregnant women taking azithromycin were prospectively followed along with two groups of matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/31\">",
"     31",
"    </a>",
"    ]. The incidence of major malformations was similar in the azithromycin-exposed and unexposed groups and was not more than the 1 to 3 percent that would be expected in the general population. All three of the malformations occurred in the infants of azithromycin-exposed women who were treated for five days for upper respiratory tract infections. This study was underpowered to detect a difference between the azithromycin-exposed and unexposed groups. The safety of this agent in pregnant women is not definitively known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clarithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is a pregnancy category C drug (ie, risk cannot be ruled out) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/32\">",
"     32",
"    </a>",
"    ]. Teratogenic effects (including cleft palate, cardiovascular anomalies, and fetal growth restriction) have occurred in monkeys, rats, mice, and rabbits with plasma clarithromycin concentrations 2 to 17 times the levels normally achieved in humans. The labeling states that no adequate and well-controlled trials in pregnant women have been performed; as a result, clarithromycin should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Telithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     Telithromycin",
"    </a>",
"    is a pregnancy category C drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). In rats and rabbits at high doses, maternal toxicity may result in delayed fetal maturation; in rats, it is excreted in breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer macrolides are generally better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . Because of its more frequent gastrointestinal side effects and risk of QT prolongation and sudden death, erythromycin is now rarely recommended. Erythromycin was the first macrolide to be associated with QT prolongation, but subsequent reports and studies have also described QT prolongation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , as well as the ketolide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following provides a brief summary of some of the major adverse effects associated with these drugs. These issues are discussed in detail separately. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?24/52/25409?source=see_link\">",
"     \"Azithromycin: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=see_link\">",
"     \"Clarithromycin: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     \"Telithromycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/6/42080?source=see_link\">",
"     \"Erythromycin: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264150671\">",
"    <span class=\"h3\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmarketing reports have identified various hepatic abnormalities in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , including abnormal liver function tests, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure; some of these cases have resulted in death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/34\">",
"     34",
"    </a>",
"    ]. Azithromycin is therefore contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use. It should be discontinued immediately if signs or symptoms of hepatitis occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264150664\">",
"    <span class=\"h3\">",
"     Telithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hepatotoxicity reported in three patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    prompted an FDA Public Health Advisory (",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htm\">",
"     www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107824.htm",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/35\">",
"     35",
"    </a>",
"    ]. All three patients developed jaundice and abnormal liver function. One patient recovered, one required an organ transplant, and one died. Liver histology in the latter two patients showed massive tissue death. Although two patients reported some alcohol use, all three had been previously healthy and were not using other prescription drugs. There have been additional reports of hepatotoxicity, 42 of which were reviewed in detail and published [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/36\">",
"     36",
"    </a>",
"    ]. The onset was short (median 10 days) and mortality was high.",
"   </p>",
"   <p>",
"    Clinicians are cautioned to monitor patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    for signs and symptoms of liver dysfunction and are advised to stop the medication in any patient who develops evidence of liver disease. Telithromycin should not be readministered to patients with a previous history of hepatitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaundice associated with the use of telithromycin or any macrolide antibiotic.",
"   </p>",
"   <p>",
"    Due to postmarketing reports of hepatotoxicity and other toxicities, the FDA rescinded its approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    for bronchitis and sinusitis. It is still approved for the treatment of mild to moderate community-acquired pneumonia, but the FDA concluded that telithromycin should be a secondary alternative to other antimicrobial drugs. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Warnings about telithromycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 2 to 5 percent of patients with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and about 12 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. Clarithromycin does not form the anhydrohemiketal degradation product thought to be responsible for some of the gastrointestinal side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/19\">",
"     19",
"    </a>",
"    ]. Macrolides have a dose-related effect on motilin receptors and can thereby stimulate the smooth muscle of the gastrointestinal tract. In fact, they have been used clinically to stimulate gastric motility [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intravenous formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    also causes gastrointestinal side effects including: nausea (4 to 7 percent), vomiting (1.4 percent), diarrhea (4 to 9 percent), and abdominal pain (2 to 3 percent).",
"   </p>",
"   <p>",
"    The response to one drug does not necessarily predict that to the other. Some patients, for example, have intolerable side effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and vice versa. Abdominal cramping with subsequent loose stools is common with high doses of azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/4,19\">",
"     4,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysgeusia seems to be a relatively frequent complaint in patients who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , less so with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    , and not with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . The clarithromycin pediatric suspension is bitter-tasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    was the first macrolide to be associated with QT interval prolongation, but subsequent reports and studies have also described QT interval prolongation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , as well as the ketolide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    . Clinicians should assess the risk of torsades de pointes when considering a macrolide and other antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition to macrolides, certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H30#H30\">",
"     \"Fluoroquinolones\", section on 'QT interval prolongation and arrhythmia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H6#H6\">",
"     \"Acquired long QT syndrome\", section on 'Incidence with specific drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, each patient's medication list should be reviewed to determine if he or she is taking more than one drug that can prolong the QT interval (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) since such patients are at increased risk of torsades de pointes (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Information regarding the risk of QT prolongation with each macrolide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    is summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      &mdash; Erythromycin is associated with an approximate two-fold increase in the risk of sudden cardiac death overall and a five-fold increase in patients also taking CYP3A4 inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      &mdash; In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients at particular risk include those with existing QT interval prolongation, hypokalemia, hypomagnesemia, significant bradycardia, bradyarrhythmias, uncompensated heart failure, and those receiving certain antiarrhythmic drugs (eg, class IA [",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ] or class III [",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ] antiarrhythmic drugs) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/38,40,41\">",
"       38,40,41",
"      </a>",
"      ]. Elderly patients may also be more susceptible to drug-associated QT interval prolongation. The warning was based on a review that followed the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a large database analysis of adults aged 30 to 74 years enrolled in Medicaid in Tennessee, patients receiving a five-day course of azithromycin had an increased risk of cardiovascular mortality (hazard ratio [HR] 2.88, 95% CI 1.79-4.63) and all-cause mortality (HR 1.85, 95% CI 1.25-2.75) compared with those who took no antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients receiving azithromycin also had an increased risk of cardiovascular mortality (HR 2.49, 95% 1.38-4.50) and all-cause mortality (HR 2.02, 95% CI 1.24-3.30) compared with those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . In contrast, there was no increase in the risk of death in patients receiving amoxicillin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      . The risk of cardiovascular mortality and all-cause mortality were similar for azithromycin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The absolute increase in cardiovascular mortality was small; patients who received azithromycin had an estimated 47 additional cardiovascular deaths per million courses of therapy compared with amoxicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/42\">",
"       42",
"      </a>",
"      ]. The risk of cardiovascular mortality was highest among patients with elevated cardiovascular risk scores; compared with patients receiving amoxicillin, in patients receiving azithromycin, there were nine excess cardiovascular deaths per million five-day courses of antibiotics among those in the lowest cardiovascular risk category versus 245 excess cardiovascular deaths among those in the highest category. Among the 29 cardiovascular deaths that occurred during a five-day course of azithromycin, 22 were sudden cardiac deaths. Although the investigators used propensity analysis to adjust for baseline risk, residual confounding remains a concern since patients prescribed azithromycin may have had a higher risk of death because of their underlying disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      comorbidities.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      &mdash; Clarithromycin has also been associated with QT interval prolongation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/43,44\">",
"       43,44",
"      </a>",
"      ], and is metabolized by CYP3A4. Torsades de pointes has primarily been described when clarithromycin is given with other drugs that prolong the QT interval. A few case reports have described torsades de pointes with clarithromycin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       Telithromycin",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Telithromycin can also prolong the QT interval. The product labeling specifies that telithromycin should be avoided in patients with congenital long QT syndrome, ongoing proarrhythmic conditions, significant bradycardia, and those taking class 1A or III antiarrhythmic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe reactions are rare but possible with all three macrolides. These include anaphylaxis, Stevens-Johnson syndrome, and pseudomembranous colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. A severe reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may persist for several days due to its long half-life. Irreversible hearing loss has been reported with azithromycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Reversible hearing loss has also been reported following macrolide use, especially when they have been given at high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Interstitial nephritis has been reported with erythromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, several other rare side effects have occurred with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    , including fatal hepatotoxicity, fatal exacerbation of myasthenia gravis, loss of consciousness, and acute interstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/33,53-56\">",
"     33,53-56",
"    </a>",
"    ]. Visual disturbances (eg, blurry vision, diplopia, difficulty focusing) can also occur and may be related to telithromycin's effects on nicotinic acid receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/57\">",
"     57",
"    </a>",
"    ]. Telithromycin is contraindicated in patients with myasthenia gravis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Warnings about telithromycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macrolides have a variety of drug interactions, many of which are mediated by inhibition of hepatic cytochrome CYP (P450) 3A enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/58\">",
"     58",
"    </a>",
"    ]. In contrast to the other macrolides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    does not appear to affect hepatic enzymes significantly, leading to fewer documented drug interactions. However, several clinically-important drug interactions have been reported with all of these agents. For example, fatalities have been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and there are now specific colchicine dose reduction recommendations published [",
"    <a class=\"abstract\" href=\"UTD.htm?1/30/1514/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These interactions are listed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=see_link\">",
"     \"Azithromycin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     \"Clarithromycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     \"Telithromycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=see_link\">",
"     \"Erythromycin (systemic): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific interactions between any two medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264149919\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      (Zithromax) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (Biaxin) are macrolide antibiotics that are used in the treatment of community-acquired respiratory tract infections. They are derivatives of the older macrolide antibiotic,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       Telithromycin",
"      </a>",
"      (Ketek) is the first member of the ketolide class of antimicrobials, which is related to the macrolide class. Concerns about postmarketing reports of hepatotoxicity and exacerbations of myasthenia gravis have led to significant restrictions on the use of telithromycin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Warnings about telithromycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of action of the newer macrolides is similar to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      . They bind to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation, translocation, chain elongation and, ultimately, bacterial protein synthesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action and chemical structure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural changes have made the newer macrolides more acid-stable than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , providing improved oral absorption, tolerance, and pharmacokinetic properties. The newer macrolides also have a broader spectrum of antibacterial activity than erythromycin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action and chemical structure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two main mechanisms of acquired macrolide resistance have been described:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Methylases encoded by the erm (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ribosome methylase) genes (ermA, ermB, ermC) alter the macrolide binding site on the bacterial ribosomal RNA, usually conferring a high degree of macrolide resistance as well as resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Active macrolide efflux pumps, encoded by the mef (macrolide efflux) msrA and msrB genes, confer a low to moderate degree of macrolide resistance These mechanisms are responsible for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      -resistance in most gram-positive cocci (eg, Staphylococcus aureus, Streptococcus pneumoniae, Staphylococcus aureus, other streptococci). In contrast to the mechanisms of acquired resistance, intrinsic resistance exhibited by Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp is due to decreased permeability of the outer cell envelope. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      have a broader spectrum of activity than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , and include activity against respiratory tract pathogens such as Streptococcus pneumoniae, Haemophilus spp, Moraxella catarrhalis, and atypical pneumonia pathogens, as well as against various other gram-negative bacteria and Mycobacterium avium complex. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of its more frequent gastrointestinal side effects and the earlier appreciation of the risk of QT prolongation and sudden death,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      is rarely recommended. However, subsequent reports and studies have also described QT prolongation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , as well as the ketolide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       telithromycin",
"      </a>",
"      . Postmarketing reports have also identified various hepatic abnormalities in patients receiving azithromycin, including cases that have resulted in death. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The macrolides have a variety of drug interactions, many of which are mediated by inhibition of hepatic cytochrome CYP (P450) 3A enzymes. In contrast to the other macrolides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      does not appear to affect hepatic enzymes significantly, leading to fewer documented drug interactions. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/1\">",
"      Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992; 26:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/2\">",
"      Rapp RP, McCraney SA, Goodman NL, Shaddick DJ. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994; 28:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/3\">",
"      Neu HC. New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med 1992; 116:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/4\">",
"      Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992; 26:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/5\">",
"      Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/6\">",
"      Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/7\">",
"      Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/8\">",
"      Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/9\">",
"      Cetin ES, Gunes H, Kaya S, et al. Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among clinical staphylococcal isolates in a Turkish university hospital. J Microbiol Immunol Infect 2010; 43:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/10\">",
"      Aktas Z, Aridogan A, Kayacan CB, Aydin D. Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey. J Microbiol 2007; 45:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/11\">",
"      Lina G, Quaglia A, Reverdy ME, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/12\">",
"      Chollet R, Chevalier J, Bryskier A, Pag&egrave;s JM. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 2004; 48:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/13\">",
"      Goldstein F, Vidal B, Kitzis MD. Telithromycin-resistant Streptococcus pneumoniae. Emerg Infect Dis 2005; 11:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/14\">",
"      Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/15\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/16\">",
"      O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/17\">",
"      File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005; 115:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/18\">",
"      Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992; 26:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/19\">",
"      Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/20\">",
"      Azithromycin extended-release (Zmax) for sinusitis and pneumonia. Med Lett Drugs Ther 2005; 47:78.",
"     </a>",
"    </li>",
"    <li>",
"     Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.396.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/22\">",
"      Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001; 45:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/23\">",
"      Wellington K, Noble S. Telithromycin. Drugs 2004; 64:1683.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information for Zithromax, Biaxin, Physicians' Desk Reference, 1995.",
"    </li>",
"    <li>",
"     Brater, DC. Pocket Manual of Drug Use in Clinical Medicine, 6th ed, Improved Therapeutics, Indianapolis 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/26\">",
"      Ross DB. The FDA and the case of Ketek. N Engl J Med 2007; 356:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/27\">",
"      Soreth J, Cox E, Kweder S, et al. Ketek--the FDA perspective. N Engl J Med 2007; 356:1675.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation, 4th ed, Williams &amp; Wilkins, Baltimore 1994. p.335.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/29\">",
"      Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol 1994; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/30\">",
"      Adair CD, Gunter M, Stovall TG, et al. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998; 91:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/31\">",
"      Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     Product Information for clarithromycin tablets. Abbott Laboratories, revised January, 1997.",
"    </li>",
"    <li>",
"     Aventis Pharmaceuticals. Ketek product labeling. 2005.",
"    </li>",
"    <li>",
"     Zithromax (azithromycin) tablet, single-dose packet, IV for injection, and oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm225814.htm (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/35\">",
"      Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/36\">",
"      Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/37\">",
"      Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007; 356:820.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/39\">",
"      Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/42\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/43\">",
"      Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002; 303:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/44\">",
"      Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/45\">",
"      Kamochi H, Nii T, Eguchi K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/46\">",
"      Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 2000; 109:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/47\">",
"      Coulston J, Balaratnam N. Irreversible sensorineural hearing loss due to clarithromycin. Postgrad Med J 2005; 81:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/48\">",
"      Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/49\">",
"      Vasquez EM, Maddux MS, Sanchez J, Pollak R. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin. Arch Intern Med 1993; 153:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/50\">",
"      Bizjak ED, Haug MT 3rd, Schilz RJ, et al. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy 1999; 19:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/51\">",
"      Hajiioannou JK, Florou V, Kousoulis P, et al. Clarithromycin induced reversible sensorineural hearing loss. B-ENT 2011; 7:127.",
"     </a>",
"    </li>",
"    <li>",
"     EES (erythromycin ethylsuccinate) granules for oral suspension and Ery-Ped (erythromycin ethylsuccinate) liquids. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; January 2011 file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm243753.htm (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/53\">",
"      Telithromycin (Ketek) for respiratory infections. Med Lett Drugs Ther 2004; 46:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/54\">",
"      Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006; 67:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/55\">",
"      Jennett AM, Bali D, Jasti P, et al. Telithromycin and myasthenic crisis. Clin Infect Dis 2006; 43:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/56\">",
"      Tintillier M, Kirch L, Almpanis C, et al. Telithromycin-induced acute interstitial nephritis: a first case report. Am J Kidney Dis 2004; 44:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/57\">",
"      Bertrand D. Importance of nicotinic acetylcholine receptors in the visual adverse effects associated with telithromycin. Biochem Pcol 2009; 78:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/58\">",
"      Thomason AR, Waldrop BA, Price SO. Nortriptyline cardiac toxicity from a probable interaction with telithromycin. Hosp Pharm 2009; 44:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/30/1514/abstract/59\">",
"      Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291.",
"     </a>",
"    </li>",
"    <li>",
"     Colcrys. file://www.colcrys.com/ (Accessed on May 24, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 474 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1514=[""].join("\n");
var outline_f1_30_1514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H264149919\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION AND CHEMICAL STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      METABOLISM AND PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acid stability and food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tissue and intracellular penetration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Active metabolites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clarithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Warnings about telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clarithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264150671\">",
"      - Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264150664\">",
"      - Telithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264149919\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=related_link\">",
"      Azithromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/52/25409?source=related_link\">",
"      Azithromycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=related_link\">",
"      Clarithromycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/8/12421?source=related_link\">",
"      Clarithromycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23159?source=related_link\">",
"      Clindamycin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=related_link\">",
"      Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/6/42080?source=related_link\">",
"      Erythromycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=related_link\">",
"      Telithromycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_30_1515="Reducing pediatric lead exposure";
var content_f1_30_1515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Provider steps in reducing continued lead exposure in children with elevated blood lead levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Report to appropriate health authorities (eg, city, county, or state health department).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Take emergency measures to reduce lead exposure. Relocate the child and family to lead-free housing if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Initiate intensive blood lead screening and/or chelation as determined by the degree of the child's blood lead elevation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Educate the family about sources of lead exposure so that they can be eliminated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Follow-up on long-term abatement procedures to reduce lead exposure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1515=[""].join("\n");
var outline_f1_30_1515=null;
var title_f1_30_1516="Male infertility unproven Rx";
var content_f1_30_1516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empirical therapy which is unproven or ineffective for male infertility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hormones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Androgens (mesterolone)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Androgen withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gonadotropins*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gonadotropin-releasing hormone*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiestrogens (clomiphene, tamoxifen)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aromatase inhibitor (testolactone, anastrazole, letrozole)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alpha adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kallikrein",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentoxifylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin E",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Captopril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Zinc",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cooling of testes",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Both gonadotropins and gonadotropin-releasing hormone can be used for the specific treatment of hypogonadotropic hypogonadism.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1516=[""].join("\n");
var outline_f1_30_1516=null;
var title_f1_30_1517="Suggested equipment for temporal artery biopsy";
var content_f1_30_1517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested equipment for temporal artery biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         &nbsp;Site selection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Hand-held Doppler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Water soluble gel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Marking pen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         Site preparation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Electric hair clipper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Skin preparation solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Lidocaine cream 4%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Lidocaine 1% with 1:200,000 epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Bupivacaine 0.5% with 1:200,000 epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;1:1 mixture of Lidocaine 1% with 1:200,000 epinephrine/Bupivicaine 1% with 1:200,000 epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;10 mL syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;18 gauge needle to draw up medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;27 or 30 gauge 1-1/4 inch needle for injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"subtitle1_single\">",
"         <strong>",
"          Drapes and sponges",
"         </strong>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Sterile Mayo stand cover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Sterile towels, drape with central opening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;4 x 4 sterile gauze sponges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         &nbsp;Instruments",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Scalpel holder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Scalpel blade (no. 15) x 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Adson-Brown forceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Skin hooks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Self-retaining retractor (eg, Alm, Heiss)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Tenotomy scissors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Metzenbaum scissors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Needle holder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Hemostat clamps (curved or straight) x 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Hand-held cautery (battery powered)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Frazier suction tip, suction tubing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         Specimen collection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Ruler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Sterile specimen cup with formalin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         Skin closure and dressing",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;3-0 or 4-0 silk ties to ligate the artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;4-0 or 5-0 absorable suture for skin closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Tincture of benzoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Skin closure strips 1/4 inch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Nonadherent absorbant dressing (eg, Telfa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Transparent film dressing (eg, Tegaderm)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1517=[""].join("\n");
var outline_f1_30_1517=null;
var title_f1_30_1518="T3 resin test FDH";
var content_f1_30_1518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T3-resin test in familial dysalbuminemic hyperthroxinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiolabeled T3 (*T3) binds normally to available binding sites on TBG, but cannot bind to available sites on the abnormal albumin; as a result, the amount left over to bind to the resin is normal. The serum total T4 is high due to excess binding to the abnormal albumin, the T3-resin uptake and THBR are normal, and the serum free T4 index is high.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1518=[""].join("\n");
var outline_f1_30_1518=null;
var title_f1_30_1519="LVEF predicts six-month mortality after STEMI";
var content_f1_30_1519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75743%7ECARD%2F68071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75743%7ECARD%2F68071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    LVEF predicts six-month mortality after STEMI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 1194 patients with an acute ST segment elevation myocardial infarction (STEMI) treated with thrombolysis, the resting left ventricular (LV) ejection fraction (LVEF) measured by radionuclide angiography (RNA) was a powerful predictor of six-month mortality. The highest risk group was those with a LVEF &lt;30 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Burns RJ, Gibbons RJ,&nbsp;Yi Q, et al. J Am Coll Cardiol 2002; 39:30.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LVEF predicts one-year mortality after STEMI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 3197 patients with an acute ST elevation myocardial infarction (STEMI) who were treated with thrombolytic therapy in the TIMI II trial, the one-year mortality correlated with the resting left ventricular ejection fraction (LVEF) measured by radionuclide ventriculography obtained within 14 days of the event. The mortality was highest in patients with an LVEF &lt;30 percent (9.9 percent). Patients not undergoing study for any reason had an intermediate mortality of 6.6 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Zaret BL, Wackers FJ, Terrin ML, et al. J Am Coll Cardiol 1995; 26:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_30_1519=[""].join("\n");
var outline_f1_30_1519=null;
